

# International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 1: acute respiratory infections

Martin Schwellnus <sup>1,2</sup> Paolo Emilio Adami <sup>3</sup> Valerie Bougault <sup>4</sup>  
 Richard Budgett,<sup>5</sup> Hege Havstad Clemm,<sup>6,7</sup> Wayne Derman <sup>2,8</sup> Uğur Erdener,<sup>5</sup>  
 Ken Fitch <sup>9</sup> James H Hull <sup>10,11</sup> Cameron McIntosh,<sup>12</sup> Tim Meyer <sup>13</sup>  
 Lars Pedersen <sup>14</sup> David B Pyne,<sup>15</sup> Tonje Reier-Nilsen,<sup>16,17</sup>  
 Wolfgang Schobersberger <sup>18</sup> Yorck Olaf Schumacher <sup>19</sup> Nicola Sewry <sup>1,2</sup>  
 Torbjørn Soligard <sup>5</sup> Maarit Valtonen <sup>20</sup> Nick Webb <sup>21</sup>  
 Lars Engebretsen<sup>5,17</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bjsports-2022-105759>).

For numbered affiliations see end of article.

## Correspondence to

Professor Martin Schwellnus, Sport, Exercise Medicine and Lifestyle Institute, University of Pretoria Faculty of Health Sciences, Pretoria 0084, South Africa; [mshwell@iafrica.com](mailto:mshwell@iafrica.com)

Accepted 4 July 2022

## ABSTRACT

Acute illnesses affecting the respiratory tract are common and form a significant component of the work of Sport and Exercise Medicine (SEM) clinicians. Acute respiratory illness (ARill) can broadly be classified as non-infective ARill and acute respiratory infections (ARinf). The aim of this consensus is to provide the SEM clinician with an overview and practical clinical approach to ARinf in athletes. The International Olympic Committee (IOC) Medical and Scientific Commission appointed an international consensus group to review ARill (non-infective ARill and ARinf) in athletes. Six subgroups of the IOC Consensus group were initially established to review the following key areas of ARill in athletes: (1) epidemiology/risk factors for ARill, (2) ARinf, (3) non-infective ARill including ARill due to environmental exposure, (4) acute asthma and related conditions, (5) effects of ARill on exercise/sports performance, medical complications/return-to-sport and (6) acute nasal/vocal cord dysfunction presenting as ARill. Several systematic and narrative reviews were conducted by IOC consensus subgroups, and these then formed the basis of sections in the consensus documents. Drafting and internal review of sections were allocated to 'core' members of the consensus group, and an advanced draft of the consensus document was discussed during a meeting of the main consensus core group in Lausanne, Switzerland on 11 to 12 October 2021. Final edits were completed after the meeting. This consensus document (part 1) focusses on ARinf, which accounts for the majority of ARill in athletes. The first section of this consensus proposes a set of definitions and classifications of ARinf in athletes to standardise future data collection and reporting. The remainder of the consensus paper examines a wide range of clinical considerations related to ARinf in athletes: epidemiology, risk factors, pathology/pathophysiology, clinical presentation and diagnosis, management, prevention, medical considerations, risks of infection during exercise, effects of infection on exercise/sports performance and return-to-sport guidelines.

## INTRODUCTION

The International Olympic Committee (IOC) Medical and Scientific Commission identified 'protection of the health of athletes' as an important focus involving prevention,<sup>1</sup> management and safe return to sport (RTS) after acute illness in athletes.

## Key points

- ⇒ Acute illnesses account for up to ~50% of all medical consultations at major sporting events, with ~50% of all acute illnesses involving the respiratory system.
- ⇒ Acute respiratory infections (ARinf) account for most of the acute respiratory illnesses in athletes and are caused primarily by viruses.
- ⇒ ARinf involve predominantly the upper airways and two clinical syndromes (ie, acute viral rhinitis/rhinosinusitis with or without systemic symptoms) are responsible for most ARinf in athletes.
- ⇒ Sport and Exercise Medicine clinicians can implement a practical clinical approach to the diagnosis, management, return-to-sport decision making and prevention of ARinf in athletes.

Management and prevention of acute illness in athletes forms a significant component of the work of Sport and Exercise Medicine (SEM) clinicians at international single-sport<sup>2-9</sup> and multisport events such as the Olympics,<sup>10-14</sup> Paralympic Games<sup>15-17</sup> and Youth Olympics.<sup>18 19</sup> Approximately 50% of all medical consultations at these events relate to acute illness in athletes, with the respiratory system consistently the most common organ system affected.<sup>4 7 8 11 12 20 21</sup> Acute respiratory illness (ARill) can occur as a result of multiple causes, which can be broadly classified as non-infective or infective. In most studies to date,<sup>22</sup> acute respiratory infections (ARinf) in athletes were diagnosed by history and clinical assessment without laboratory confirmation of an infection, or identification of a specific pathogen and are 'suspected' ARinf.<sup>4 7 8 10 12</sup>

The aim of this consensus statement is to provide the SEM clinician with an overview and practical clinical approach to ARinf in athletes. This document forms part 1 of a three-part series, with part 2 focusing on non-infective ARill in athletes<sup>23</sup> and part 3 on SARS-CoV-2 infection in athletes.<sup>24</sup> The specific focus of part 1 is to review clinically relevant



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Schwellnus M, Adami PE, Bougault V, et al. *Br J Sports Med* Epub ahead of print: [please include Day Month Year]. doi:10.1136/bjsports-2022-105759

aspects of ARinf in athletes. The first section of this manuscript proposes a set of definitions and classifications of ARinf in athletes to standardise future data collection and reporting. The remainder of this IOC consensus examines a wide range of clinical considerations related to ARinf in athletes: epidemiology, risk factors, pathology/pathophysiology, clinical presentation and diagnosis, management, prevention, medical considerations and risks of illness during exercise, effects of illness on exercise/sports performance and RTS decisions.

The work of this consensus group started in September 2019, before the COVID-19 pandemic. As the pandemic emerged in 2020, the work of IOC consensus group was expanded with the formation of subgroup 7, which was tasked to focus on SARS-CoV-2 infection in the athlete. The focus of this part 1 of the consensus was on all ARinf in athletes, but as new data on SARS-CoV-2 infection in athletes emerged from March 2020, several research findings that are generally applicable to ARinf were identified, and these are included in this part 1 consensus. As indicated, the specific work of subgroup 7 forms a separate IOC consensus on SARS-CoV-2 infection in athletes (part 3).

## METHODS

The process to generate this consensus statement involved several steps: (1) to identify SEM experts in the field, nomination forms (detailing key publications in the field, clinical experience and professional motivations) were widely distributed by the IOC Medical Commission and Scientific Department to all contacts in the IOC Research Centres for Prevention of Injury and Protection of Athlete Health, National Olympic Committee medical staff in past Olympic Games, and participants of past meetings and conferences such as the IOC World Conference on Prevention of Injury and Illness in Sport and IOC advanced team physician courses; (2) nominations were considered, and members then invited as either 'core' or 'corresponding' members ('core' members coordinated the preparation of specific consensus sections and 'core' and 'corresponding' members were involved with reviewing literature, collating data and conducting systematic and narrative reviews in six focus areas), the final 'core' group included representation from a former Olympic athlete (CM); (3) various areas of ARill were originally identified including ARinf and non-infective ARill such as acute asthma and related conditions, causes of nasal obstruction, and acute nasal/vocal cord dysfunction presenting as ARill; (4) each subgroup held online meetings to discuss broad content and formulate a systematic (with or without meta-analyses) or narrative review(s), and data from these reviews were incorporated into the main consensus documents; (5) the draft sections of the consensus documents were allocated to 'core' members. Initial draft sections of the consensus statements were reviewed internally before further discussion and finalisation of the consensus document at a meeting conducted in Lausanne, Switzerland on 11 to 12 October 2021. Final edits were completed in a 3-month period after the meeting, prior to submission of the manuscript.

## TERMINOLOGY, DEFINITIONS AND CLASSIFICATION OF ARINF IN ATHLETES

ARill in athletes, and specifically ARinf, can be categorised based on an anatomical and pathological classification. For the purposes of this consensus document, terminology and anatomical/pathological classifications of ARill and ARinf were agreed on by the consensus group early in the process and finalised after an online meeting in January 2021. Non-infective ARill was defined as an illness not caused by infection from a specific

pathogen, by clinical diagnosis or laboratory investigation(s). There are several conditions that cause non-infective ARill and these are comprehensively reviewed in part 2 of the IOC Consensus statement on ARill in athletes.<sup>23</sup>

### Anatomical classification of ARinf in athletes

Due to the structural and functional connection between upper and lower airways, there is a pathological continuum in many conditions causing ARill including allergy, asthma, infection and other inflammatory conditions related to pollution and chemical exposure.<sup>25 26</sup> However, the terms 'upper' or 'lower' respiratory tract disease are still used commonly when referring to both non-infective and infective causes of ARill. In this context, 'upper' ARinf refers to symptoms, signs, and pathological features of infective conditions above and including the larynx (nose, sinuses, pharynx, larynx), while 'lower' ARinf refers to symptoms, signs, and pathological features of infective conditions below the level of the larynx (trachea, bronchi, lungs and pleura). The consensus group adopted use of the term 'predominantly' for upper or lower ARinf, based on the main clinical (cluster of upper or lower symptoms, signs) or pathological features involving the 'upper' or 'lower' airways.

### Pathological classification of ARinf in athletes

Historically, in many studies reporting on ARill in athletes,<sup>22</sup> the pathology could not be attributed specifically to an infection or a non-infective cause, and/or these details were not specified explicitly in the study design or methods section. When analysing data from these studies, the consensus group defined the ARill as an 'undiagnosed' ARill. In studies where an infection was reported, the infection was often not confirmed and/or the specific viral, bacteriological, or other pathogens causing the infection were not identified. In these cases, the consensus group classified the ARinf as 'suspected' rather than 'confirmed'. For the purposes of this consensus statement, the following broad classification, and methods to diagnose ARinf used in studies to date, were agreed on and applied for this document (table 1). This table, featuring the methods to diagnose and classify ARinf, is adapted from two systematic reviews conducted by specific subgroups.<sup>22 27</sup>

A 'suspected' ARinf was defined as ARill presenting with general symptoms and/or physical signs suggestive of an ARinf, but where the specific pathogen causing an infection was not confirmed by laboratory testing. In published studies of ARinf in athletes, the following methods were used to classify 'suspected' ARinf: (1) self-reported symptoms, coupled with an algorithm that was validated for the diagnosis of ARinf. The validated questionnaires included the Wisconsin Upper Respiratory Symptom Survey-21,<sup>28</sup> the Jackson Cold Scale,<sup>29</sup> or other questionnaires where the severity of the symptoms was scored to provide a quantitative assessment,<sup>30 31</sup> (2) a review of self-reported symptoms of an ARinf by a physician, but without clinical or laboratory evaluation, or (3) clinical diagnosis of an ARinf by a physician, based on history and clinical examination.

A 'confirmed' ARinf was defined as an ARinf diagnosed by a physician with laboratory evidence confirming an infection. A 'confirmed' ARinf could then be further classified as either: (1) a confirmed ARinf but where the specific pathogen was not identified or (2) a confirmed ARinf where a specific pathogen (predominantly viral and less commonly bacterial) was identified by polymerase chain reaction (PCR) testing on specimens, culture of an organism from specimens, or serology (eg, rise in antibody titres) (table 1).

**Table 1** Classification and methods to diagnose acute respiratory infection (ARInf) in athletes (adapted from Derman *et al*<sup>22</sup>)

Classification	Methods to diagnose	Notes/description
▶ Suspected ARInf	<ul style="list-style-type: none"> <li>▶ Self-reported symptoms combined with an algorithm that has been validated for ARInf</li> <li>▶ Self-reported symptoms of an ARInf reviewed by a physician, but without clinical or laboratory evaluation</li> <li>▶ Clinical diagnosis of an ARInf by a physician, based on history and clinical examination</li> </ul>	<ul style="list-style-type: none"> <li>▶ General symptoms and/or physical signs suggestive of an ARInf, but where the specific pathology of an infection was not confirmed</li> <li>▶ A variety of validated questionnaires can be used and include the following: Wisconsin Upper Respiratory Symptom Survey-21,<sup>28</sup> Jackson Cold Scale,<sup>29</sup> other questionnaires in which the severity of the symptoms were scored to provide a quantitative assessment (Australian Institute of Sport (AIS) Symptom log).<sup>30</sup></li> </ul>
▶ Confirmed ARInf but no pathogen identified	▶ Clinical diagnosis of ARInf by a physician that was confirmed by laboratory investigation as an infective cause	▶ Special investigations can be used to confirm the diagnosis of an infection, but these do not identify the specific pathogen: Investigations include: full blood count results, raised biomarker of systemic inflammation (C reactive protein)
▶ Confirmed ARInf and pathogen identified	▶ Clinical diagnosis of ARInf by a physician that was confirmed by laboratory investigation to identify a specific pathogen	<ul style="list-style-type: none"> <li>▶ Special investigations that can be used to confirm the specific pathogen causing the ARInf, include: PCR testing on specimen(s), culture of an organism from specimen(s), or serology (eg, rise in antibody titres)</li> <li>▶ In some cases, a diagnosis of an ARInf caused by a specific pathogen may also be regarded as confirmed when diagnostic clinical features with a high sensitivity and specificity are present in suspected cases</li> <li>▶ In such case there is also a high pretest probability of an ARInf (eg, a history and typical rash in an athlete where there is a confirmed viral outbreak in a travelling team, or during an epidemic/pandemic)</li> </ul>

## PATHOLOGY AND PATHOPHYSIOLOGY OF ARINF IN ATHLETES

### Pathogens causing ARInf

ARInfs are mostly caused by different viruses, occasionally by bacteria, and rarely by other pathogens (eg, fungal).<sup>32</sup> In the general population, a viral aetiology accounts for >80% of all upper ARInf.<sup>33–35</sup> At least 10 different respiratory viruses species with hundreds of subtypes cause most ARInf in the general population (table 2), but there are many subtypes and serotypes.<sup>34</sup> Clinically non-significant bacterial colonisation can also be combined with viral pathogen identification, as has been shown in 5% to 10% of adults with upper ARInf.<sup>35</sup>

The specific pathogens causing ARInf in athletes have not been studied extensively, but the same pathogens cause ARInf in athletes as in the general adult population. Prior to the COVID-19 pandemic, rhinoviruses, non-SARS coronaviruses, influenza viruses and RS-viruses were identified as the most

frequent pathogens causing ARInf in athletes, but only in a few studies.<sup>36–41</sup> Since December 2019, the predominant pathogen causing ARInf in the general population was the novel coronavirus, SARS-CoV-2.

As in the general population, pathogens cannot be detected in all athletes presenting with symptoms of ARInf. Early studies conducted in Australia<sup>36 38</sup> reported viral aetiology in one-third of athletes with symptoms of respiratory infection. In contrast, more recent studies from Finland showed a higher detection rate of viral causes (77%) in athletes with symptoms of ARInf.<sup>39 40</sup> This higher detection rate, which is similar to reports in the general adult population, may be explained by several factors including: expected viral epidemics of winter season, winter sport disciplines, and methodological variations. In more recent studies four different multiplex PCR panels were used to identify pathogens.<sup>32 42 43</sup> These studies indicate that athletes presenting with mild symptoms of respiratory infection are likely to have a viral aetiology. However, more prospective studies in larger athlete populations with a longer surveillance and follow-up time are needed. Bacterial causes of ARInf in athletes are described but are uncommon.<sup>44</sup> As in the general population, the cause of ARInf in athletes has also been dominated by SARS-CoV-2 infection since December 2019.<sup>45–49</sup>

### Pathophysiology of ARInf

Respiratory pathogens circulate commonly in all age groups by an efficient person-to-person transmission. The transmission pathways are dependent on the pathogen and include aerosol, droplet, as well as direct or indirect contact transmission.<sup>50</sup> A detailed discussion of the pathophysiology of respiratory tract infection by viral and bacterial pathogens is beyond the scope of this consensus, and has been reviewed elsewhere.<sup>51 52</sup> In general, on entry of the respiratory tract, viruses invade the respiratory epithelium, gain entry to the cells, elicit an inflammatory response, replicate, cause cellular death, and subsequently shed and transmit via respiratory secretions.<sup>51 53</sup> Bacteria, such as those causing acute pharyngitis, attach to and, in the case of group A beta-haemolytic streptococcus, invade the mucosa of the respiratory tract, elicit an inflammatory response, cause cell death and may form an adherent exudate.<sup>51</sup>

The pathophysiological mechanisms responsible for the common general symptoms of ARInf are related to a non-specific acute phase response, as well as local tissue injury by the pathogen. In the early stages of the infection, the non-specific acute phase response results in the systemic release of several cytokines, which collectively are an important component of

**Table 2** More common pathogens (viral, bacterial) causing acute respiratory infection in the general population<sup>32 34</sup>

Pathogen	Subtypes
Viruses	
	<i>RNA viruses</i>
	Influenza types A and B
	Parainfluenza types 1, 3 and 4
	Respiratory syncytial virus A and B
	Human metapneumovirus
	Measles virus
	Rhinovirus species A, B and C
	Enterovirus
	Coronavirus NL63, OC43, HKU1, 229E
	SARS-CoV-2
	<i>DNA viruses</i>
	Adenovirus
	Cytomegalovirus
	Bocavirus
	Epstein-Barr virus
	Varicella virus
Bacteria	
	<i>Streptococcus pneumoniae</i>
	<i>Haemophilus influenzae</i>
	<i>Moraxella catarrhalis</i>
	<i>Streptococcus pyogenes</i>
	<i>Bordetella pertussis</i>
	<i>Chlamydia pneumoniae</i>
	<i>Mycoplasma pneumoniae</i>



## Consensus statement

the host defence mechanism.<sup>52</sup> Acute phase reactants (APR) are a heterogeneous group of plasma proteins that increase or decrease in concentration in response to inflammatory stimuli, including acute infection. APR such as C reactive protein (CRP) and procalcitonin (PCT) can be measured in the laboratory and are useful markers of inflammation associated with ARinf. Their response is proportional to the severity of the inflammatory stimulus of the ARinf.<sup>54</sup> In most ARinf, inflammatory mediators such as prostaglandin and bradykinin are responsible for local symptoms (rhinorrhoea and nasal congestion), while cytokines are responsible for systemic symptoms (fever, chills, headache, myalgia).<sup>52</sup> The clinical relevance of the acute phase response is that symptoms of ARinf caused by acute phase inflammatory mediators are non-specific and common to infections caused by different pathogens. As a result, symptoms of ARinf are generally non-specific and cannot be used to diagnose the underlying pathogen causing an ARinf. However, these symptoms (type, duration and severity) are related to the magnitude of the inflammatory response and can indicate the severity of the ARinf.<sup>54</sup>

Incubation period and infectiousness are two pathophysiological features of ARinf that have specific clinical relevance to the SEM clinician. The incubation period (defined as the time from pathogen exposure to onset of signs and symptoms) is pathogen-dependent, and varies from 1 to 14 days (eg, rhinovirus=1–3 days; adenovirus=7–13 days and SARS-CoV-2=2–14 days).<sup>33 55 56</sup> Knowledge of the incubation period is important for the SEM clinician because it informs clinical decision making when controlling viral epidemics within teams.<sup>39 40</sup>

Until recently, viral shedding time was used to determine the duration of infectiousness, but this concept is changing due to the increased knowledge of SARS-CoV-2. Shedding time of respiratory viruses can range from a few days up to weeks, but the time of infectiousness during the detection of viral agent is often not known.<sup>57</sup> The risk of viral transmission is highest during the first 3–4 days of the infection and in the case of SARS-CoV-2, up to 48 hours before the onset of symptoms. Infectiousness is an important determinant in decision making on the duration of quarantining infected athletes, and when an athlete can return to team practice, locker rooms and shared transportation.

### Potential complications in other organ/organ systems, other than the upper respiratory tract, that can be associated with an ARinf

Although the majority of ARinf only result in pathology within the upper respiratory tract, there are potential regional systemic and complications in other organs/organ systems caused by respiratory viral pathogens causing ARinf (online supplemental table S1). The risk and type of complications vary according to the host and the pathogen.

A systematic review of potential multiorgan complications of ARinf in athletes was commissioned and then undertaken by a subgroup of the IOC Consensus group. This review identified too few studies to analyse, therefore, data in this area are currently very limited. Although apparently very rare, particularly in younger populations, potential complications are of clinical relevance to athletes with ARinf because they can indicate more extensive or severe disease. This aspect was highlighted by studies during the recent COVID-19 pandemic indicating that, for example, reported cardiovascular complications such as myocarditis/pericarditis that can occur in athletes with SARS-CoV-2 infection. Initial studies, with small sample sizes in selected athletic cohorts, showed a high prevalence of myocarditis/pericarditis after SARS-CoV-2 infection,<sup>58 59</sup> but

in several larger studies this complication was found to be rare (<3% or less).<sup>60–62</sup> Thus, although potential complications of ARinf affecting multiple organ systems are rare, the SEM clinician should consider these complications as they may predispose athletes to an increased risk of adverse medical events during return to full training and competition.

### INCIDENCE OF ARINF IN ATHLETES

A systematic review and meta-analysis undertaken by a subgroup of the IOC Consensus group determined the incidence per 1000 athlete days of ARill, and specifically ARinf, in athletes.<sup>22</sup> This review included subanalyses based on the anatomical and pathological classification of ARill, and specifically ARinf in athletes. Data included athletes at any level of performance (elite/non-elite), aged 15–65 years. Analysis was done from data in 124 original research articles (n=128 360 athletes) published between January 1990 and July 2020.


#### Incidence of ARinf in athletes

The incidence of ARinf by pathological and anatomical classification and by method of diagnosis is summarised in [figure 1](#).

The overall pooled incidence of all ARinf (both suspected and confirmed) in athletes was 4.9 per 1000 athlete days,<sup>22</sup> and the incidence was twofold higher for predominantly upper ARinf (5.9 per 1000 athlete days) versus general (defined as combined upper and lower ARinf) ARinf (2.8 per 1000 athlete days). There was a higher incidence of ARinf in athletes with confirmed ARinf (pathogen identification) compared with all other categories of suspected ARinf. Studies in athletes with confirmed ARinf (pathogen identification)<sup>39 40</sup> were conducted in a selected cohort of elite athletes during international winter sport competition and used a different more sensitive definition of ARinf (any symptom or viral pathogen that was detected). Although the incidence of ARinf was higher in these studies, there were wide 95% CIs, and this estimate was not significantly different from the incidence of ARinf in other studies.<sup>22</sup> A higher incidence of ARinf in non-elite athletes (8.7 per 1000 athlete days) compared with elite athletes (4.2 per 1000 athlete days) was reported in the recent review. However, in a winter sport team setting, a seven-fold higher incidence of ARinf was evident in a group of elite athletes compared with age-matched controls exercising less than 6 hours per week and a control group of non-athletes.<sup>39</sup> The study was conducted during a winter viral epidemic where athletes were asked to report even mild respiratory symptoms, which may explain the difference in findings.

#### Clinical point/s: How common are acute respiratory infections (ARinf) in athletes?

- ⇒ The general incidence of ARinf in athletes equates to ~1.8 ARinf per athlete per year (in comparison to ~2.3 in the general population).
- ⇒ There is a high incidence of predominantly upper ARinf.
- ⇒ Elite athletes have a lower incidence of ARinf than non-elite athletes.
- ⇒ The incidence of suspected ARinf is similar across methods of diagnosis, indicating that Sport and Exercise Medicine clinicians can confidently use validated questionnaires and checklists to screen athletes for suspected ARinf.
- ⇒ There appears to be a higher incidence of confirmed ARinf with pathogen identification compared with suspected ARinf, but this outcome requires confirmation in future studies with larger cohorts.



**Figure 1** The incidence (per 1000 athlete days; 95% CIs) of acute respiratory infection (ARinf) by pathological and anatomical classification and by method of diagnosis (adapted from Derman *et al*<sup>22</sup>).

### RISK FACTORS ASSOCIATED WITH ARINF IN ATHLETES

A comprehensive review of the risk factors and biomarkers for both suspected and confirmed ARinf (n=24 studies) has been published by an IOC consensus subgroup.<sup>63</sup> This review included 48 studies (19 390 athletes) and the majority (71%) of studies were self-reported ARill in athletes. Sub-analyses included the pathological classification of ARinf and methods used to diagnose suspected ARinf. A summary of risk factors with a strong positive association to a high incidence of confirmed ARinf or suspected ARinf is presented below.

#### Clinical point/s: What are the risk factors associated with acute respiratory infections (ARinf) in athletes? (strong positive associations)

- ⇒ Endurance sports versus other sports.
- ⇒ Winter vs other seasons.
- ⇒ Training variables (high intensity training, increased training load, training monotony, lack of tapering).
- ⇒ Training at altitude.
- ⇒ Competition periods.
- ⇒ Travel (during and following long-haul international travel).
- ⇒ Vitamin D deficiency.

While other possible risk factors for ARinf were identified in this review, conflicting evidence limited conclusions to be drawn, and further research is warranted.

### CLINICAL PRESENTATION AND DIAGNOSIS OF ARINF IN ATHLETES

#### Introduction

Athletes with ARill who present with typical respiratory symptoms are traditionally categorised according to the predominant anatomical area affected: upper respiratory tract, lower respiratory tract/regional symptoms and systemic (whole body) symptoms. There is considerable overlap between symptoms of non-infective ARill and ARinf, but discrete symptoms and symptom clusters are more typical of ARinf than non-infective ARill (online supplemental table S2). Associated systemic symptoms, or other symptoms of multiorgan involvement, can also indicate ARinf rather than a non-infective cause of ARill (online supplemental table S2).

The clinical presentation of an ARinf is highly variable, and is influenced by several pathogen and host factors,<sup>64</sup> and ranges in severity from mildly symptomatic to life-threatening and death.<sup>34</sup> Explanations for the non-specific clinical presentation of ARinf include: (1) overlapping of some symptoms and clinical signs of ARinf and non-infective ARill, (2) the same pathogen can cause variable clinical presentations of ARinf in a group of athletes, (3) different pathogens can cause a similar ARinf clinical syndrome in the same athlete,<sup>34</sup> and (4) many symptoms are the result of a non-specific acute phase response, which are common to all infections.<sup>52</sup> Therefore, an ARinf caused by a specific pathogen cannot be diagnosed by typical symptoms and

## Consensus statement

clinical signs (clinical syndrome) alone, and laboratory tests are required for formal identification.

### Asymptomatic ARinf in athletes

Several pathogens can infect athletes, but the athlete may remain asymptomatic.<sup>64</sup> For example, in a review of adult human influenza volunteer challenge studies in the general population, 30% of influenza virus infections were asymptomatic.<sup>65</sup> In one study among athletes during the Nordic Ski World Championships, viral infections were asymptomatic in 8% of athletes of Team Finland, 19% of staff members and 22% of controls.<sup>39</sup> Data from recent studies during the COVID-19 pandemic indicate that about 20% to 30% of SARS-CoV-2 infections in athletes are asymptomatic. Asymptomatic infections are important in the SEM context because: (1) there may be a risk, although likely to be very small, of adverse medical events during exercise, (2) the potential negative effect of asymptomatic ARinf on exercise/sports performance in athletes is unclear, but again is likely to be low and (3) there is a potential risk of transmission within teams and sports events.<sup>40</sup> The importance of asymptomatic ARinf in transmission chains has been highlighted by the COVID-19 pandemic.

### Clinical syndromes of ARinf

A clinical syndrome is defined as a combination of symptoms and signs (sometimes also referred to as a clinical phenotype) that together represent a disease process. Defining and diagnosing the clinical syndrome of ARinf, plotting the time course by monitoring the progress of the symptoms and signs, and knowing the pathogen, are all important in guiding the SEM clinician in management of athletes with ARinf. These parameters are relevant to identify potential detrimental effects of ARinf on exercise and sports performance and mitigate the risk of medical complications when resuming exercise training.

Symptomatic ARinf typically presents with mild, non-specific localised upper respiratory tract symptoms such as sore throat, sneezing, rhinorrhoea and nasal congestion/stiffness.<sup>34</sup> Cough and hoarseness are variable, and can indicate either upper or lower respiratory tract involvement. Primary symptoms can emerge initially or develop after several days.<sup>34</sup> Both pathogen and host dependent symptoms of ARinf typically peak within 2–3 days after onset, are self-limited and resolve by 7–10 days in adults, both in the general population<sup>34</sup> and in athletes.<sup>27</sup> The duration of ARinf symptoms can be used as an indicator of severity of ARinf. Indicators of a more severe infection are: (1) regional symptoms (headache), (2) systemic symptoms (malaise, fever, myalgia and fatigue), (3) prolonged symptoms (lasting >7 days), (4) symptoms that increase rather than decrease in severity over time, (5) the development of new symptoms over time and (6) specific symptoms associated with multiorgan (non-respiratory) involvement.

### Classification of clinical syndromes of ARinf

Clinical syndromes of ARinf can be based on a broad anatomical classification (predominantly upper or lower respiratory tract) and underlying pathology. Although this scenario is rapidly changing, most SEM clinicians do not yet have routine access to laboratory testing methods to identify specific pathogens causing ARinf to guide their clinical decision making. In this IOC consensus, we propose a classification of the clinical syndromes of ARinf in athletes, which has been adapted from Treanor.<sup>34</sup> This classification is also based on a clinical presentation of an

ARinf predominantly affecting the upper or the lower respiratory tract.

### Clinical point/s: Classification of clinical syndromes of acute respiratory infections (ARinf) in athletes

- ⇒ Predominantly upper ARinf (>90% of all ARinf)
  - ⇒ Acute rhinitis and/or additional features of rhinosinusitis and rhinopharyngitis without regional or systemic symptoms and signs ('common cold').
  - ⇒ Acute rhinitis and/or additional features of rhinosinusitis and rhinopharyngitis with regional or systemic symptoms and signs ('influenza-like' syndrome).
  - ⇒ Acute pharyngitis.\*
  - ⇒ Acute laryngitis.\*
  - ⇒ Acute laryngotracheobronchitis.\*
- ⇒ Predominantly lower ARinf (<10% of all ARinf)
  - ⇒ Acute tracheobronchitis.\*
  - ⇒ Acute bronchitis/bronchiolitis.\*
  - ⇒ Acute pneumonia.

\*These syndromes can also present with or without systemic symptoms and signs.

Diagnosing the clinical syndromes of ARinf in athletes

#### *Clinical diagnosis of a suspected ARinf (history and clinical examination)*

Awareness of the current epidemics and a careful history of symptomatology with a clinical examination is recommended to identify the clinical syndromes of an ARinf. The case definition for each clinical syndrome as well as the broad clinical features of each clinical syndrome are summarised in [table 3](#).

#### *Special investigations to confirm the diagnosis of an ARinf (no pathogen identified)*

APRs are a heterogeneous group of plasma proteins that increase or decrease in concentration in response to inflammatory stimuli, including acute infections. There are several clinically important APRs and their potential diagnostic value has been reviewed.<sup>54 66</sup> Non-diagnostic specific markers of infection that the SEM clinician can consider as diagnostic markers are erythrocyte sedimentation rate (ESR), CRP and PCT. CRP is a better measure of the acute-phase response, more sensitive than ESR, and the preferred marker of infection. The clinical relevance of CRP is that, in response to ARinf, CRP concentration begins to rise after 12 to 24 hours and peaks within 2–3 days (50–100 mg/L). Extremely high increases in CRP (>500 mg/L) are more common in bacterial infections and severe systemic infections.<sup>54</sup> Therefore, measurement of CRP concentration in an athlete with suspected ARinf can be useful to confirm the presence of an infection.

PCT is less commonly measured but can be a useful differential biomarker for bacterial (vs viral) ARinf. PCT has been used in the early identification of bacterial lower ARinf, and to stratify patients with a higher risk of complications.<sup>54</sup> Finally, a full blood count (FBC) and differential white cell count can also be of value to distinguish non-infective ARill from ARinf in an athlete.<sup>54</sup>

#### *Special investigations to identify the causative pathogen in ARinf*

There are several methods to detect the pathogens causing the ARinf by collecting a nasopharyngeal mucosal sample with a flocked nasal swab, obtaining a sputum sample, or taking a

**Table 3** Case definitions and clinical features of acute respiratory infections (ARInf) clinical syndromes in athletes

Main anatomical classification	Clinical syndromes of ARInf in athletes	Case definition	Clinical features/notes	Refs
Predominantly upper respiratory tract	1. Acute infective rhinitis and/or additional features of rhinosinusitis/rhinopharyngitis (Also described as the 'common cold', 'Coryza', or 'viral upper respiratory infection')	A clinical presentation characterised by rhinitis (blocked/stuffy nose, runny nose, sneezing, nasal discharge) that may be associated with other symptoms and signs of an upper respiratory infection (sore throat, sinus pressure)	<ul style="list-style-type: none"> <li>▶ Regional symptoms (cough, hoarseness, cervical lymphadenopathy, watery eyes) are uncommon</li> <li>▶ Systemic symptoms (fever, headache, myalgia/arthralgia, malaise) are uncommon and if present, they are mild and transient (&lt;48 hours)</li> <li>▶ Conjunctivitis is more common with adenovirus</li> </ul>	34 51 91 118
	2. Acute infective rhinosinusitis/rhinopharyngitis with systemic symptoms/signs (Also described as 'influenza-like', or 'influenza')	A rapid-onset clinical presentation characterised by: <ul style="list-style-type: none"> <li>▶ at least one upper/regional respiratory symptom (blocked/stuffy nose, runny nose, sneezing, nasal discharge, sore throat, cough)</li> </ul> AND <ul style="list-style-type: none"> <li>▶ fever (core temperature <math>\geq 38^{\circ}\text{C}</math>) at least once in a 72 hour period</li> </ul> AND <ul style="list-style-type: none"> <li>▶ at least one systemic symptom/sign (headache, myalgia/arthralgia, excessive fatigue, malaise)</li> </ul>	<ul style="list-style-type: none"> <li>▶ Some case definitions stipulate fever, cough and fatigue as the hallmark features</li> <li>▶ WHO case definition of influenza-like illness: An ARInf with measured fever of <math>\geq 38^{\circ}\text{C}</math>, and cough and onset within the last 10 days</li> </ul>	119–126
	3. Acute pharyngitis*	A clinical presentation that is mainly characterised by a sore throat, with objective evidence of pharyngeal inflammation	<ul style="list-style-type: none"> <li>▶ Clinical features of pharyngitis (erythema, exudate) that may include cervical lymphadenopathy</li> <li>▶ May be associated with systemic symptoms (fever, headache, myalgia/arthralgia, malaise)</li> <li>▶ Aetiology can be viral, bacterial or other pathogens</li> <li>▶ Consider Epstein-Barr virus as a cause in young athletes</li> </ul>	34
	4. Acute laryngitis/laryngotracheobronchitis ('croup')*	A clinical presentation that is mainly characterised by hoarseness, sore throat and cough	<ul style="list-style-type: none"> <li>▶ Clinical features of laryngitis (hoarseness, sore/scratchy throat) that may be associated with difficulty in breathing, inspiratory stridor</li> <li>▶ Clinical features of tracheobronchitis (dry cough, wet cough, difficulty in breathing, chest pain/pressure, chest tightness)</li> <li>▶ May be associated with systemic symptoms (fever, headache, myalgia/arthralgia, malaise) but this is uncommon</li> <li>▶ Laryngotracheobronchitis (croup) is more common in children</li> </ul>	34
Predominantly lower respiratory tract	1. Acute tracheobronchitis*	A clinical presentation that is mainly characterised by cough (dry or wet) that may be associated with tracheal tenderness and other chest symptoms	<ul style="list-style-type: none"> <li>▶ Clinical features of tracheobronchitis (dry cough, wet cough, difficulty in breathing, chest pain/pressure, chest tightness, wheeze, tracheal tenderness)</li> <li>▶ May be associated with systemic symptoms (fever, headache, myalgia/arthralgia, malaise)</li> </ul>	34
	2. Acute bronchitis/bronchiolitis*	A clinical presentation that is mainly characterised by cough without evidence of pneumonia	<ul style="list-style-type: none"> <li>▶ Acute bronchitis can occur as a complication of acute rhinitis/rhinosinusitis</li> <li>▶ The aetiology of bronchitis can be viral, bacterial or other pathogens</li> <li>▶ Bronchiolitis is a clinical syndrome in infants that is characterised by upper respiratory symptoms for 2–3 days followed by lower respiratory symptoms such as wheezing and other chest symptoms/signs</li> <li>▶ May be associated with systemic symptoms (fever, headache, myalgia/arthralgia, malaise)</li> </ul>	34 127
	3. Acute pneumonia	A clinical presentation confirmed by special investigations (eg, chest X-ray) that is mainly characterised by productive cough, difficulty in breathing and pleuritic chest pain, which is associated with fever and other systemic symptoms and signs	<ul style="list-style-type: none"> <li>▶ Systemic symptoms (fever, chills, excessive fatigue, general myalgia/arthralgia, skin rash, abdominal pain, nausea, vomiting, diarrhoea, loss of appetite)</li> <li>▶ Clinical signs include tachycardia, tachypnoea, crackles, rales, tactile fremitus, and egophony</li> <li>▶ Acute pneumonia can occur as a complication of other upper respiratory infections</li> <li>▶ The aetiology of acute pneumonia can be viral, bacterial or other pathogens</li> <li>▶ Acute pneumonia is rare in healthy athletes and more common in immunocompromised individuals and those with co-morbidities</li> </ul>	34 128

\*Can present with or without systemic symptoms/signs.

blood sample for antibody testing.<sup>67</sup> Viral and bacterial culture remains the 'gold standard' for pathogen identification. For viral diagnostics, the traditional diagnostic method of culture has, in the last two decades, largely been superseded by PCR tests.<sup>68</sup> Antigen tests have proven to be useful in virus detection and control during the COVID-19 pandemic.<sup>69</sup> However, antigen tests are not able to detect all respiratory viruses, and their sensitivity in adults may be as low as 30%.<sup>70 71</sup> The commercial multiplex respiratory PCR tests are particularly useful as they can detect the genetic material (nucleic acids) of up to 16–18 respiratory viruses concurrently from a single

mucus sample.<sup>72–74</sup> Additionally bacterial targets such as *Streptococcus pneumoniae*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Haemophilus influenzae* are also included in some commercial PCR kits.<sup>75 76</sup> It is important to note that a positive PCR test does not necessarily reflect active virus replication, and associations between viral load and infectiousness remain unclear.<sup>33 77</sup> Sensitive and specific molecular test platforms, as well as fast, automated molecular point-of-care tests are becoming increasingly applicable for clinical use in SEM at international competitions such as the Olympic and Paralympic Games.<sup>39 40 78</sup> The need for routine expensive comprehensive



pathogen identification of ARinf is debatable as a specific therapeutic intervention is only available for influenza. However, the COVID-19 pandemic highlighted the importance of early recognition of symptoms, and early and precise viral pathogen identification so that athletes can be isolated quickly and quarantined to prevent spread of infection.<sup>39 40</sup>

*Special investigations to assess for regional and systemic involvement (multiorgan involvement) of ARinf*

In suspected cases of more severe and complicated ARinf, a range of special investigations can be considered to confirm the diagnosis of multiorgan involvement. The choice of special investigations will depend on the suspected involvement of the organ system/s involved. Some of the more common special investigations that the SEM clinician can consider in cases of moderate to severe ARinf in athletes are listed (online supplemental table S4). The consensus group recommends that confirmation of the diagnosis, determination of ARinf severity as well as management of regional and multiorgan complications, are best conducted in conjunction with specialist clinician colleagues.

*Determining the severity of ARinf in athletes*

There is substantial variability in the severity of illness when the same pathogen causes ARinf in multiple athletes, or when different pathogens cause ARinf in one athlete. The severity of an ARinf in athletes is dependent on numerous factors including the pathogen and host characteristics, which may be genetic or acquired. The following host (athlete) characteristics may predispose an individual to a more severe ARinf; older age, male sex, obesity and comorbidities (immune system dysfunction, immunosuppression, use of immune suppressive medications (eg, Transplant Games), hypertension, cardiovascular disease, cancer, chronic lung disease including asthma, diabetes mellitus) and Para athletes with spinal cord lesions and those of high needs. The risk of more severe ARinf is also related to vaccination status and exposure to a higher pathogen (viral) load.

Determination of what is considered a ‘more severe’ ARinf is derived from studies in the general population, particularly during the COVID-19 pandemic. In the general population, the definition of the ‘severity’ of an ARinf is based on parameters such as the presence or absence of severe symptoms (severe dyspnoea at rest), extremely low oxygen saturation, hospital admission, high care or intensive care unit admission, presence of respiratory distress requiring mechanical ventilation or death.<sup>79</sup> However, most athletes with ARinf do not have extremely low oxygen saturation, do not require hospitalisation, and would be classified with an ARinf of mild to moderate severity. Currently, there are no validated tools, algorithms or scoring systems to differentiate severity of ARinf in athletes, who fall into the majority ‘mild to moderate severity’ category.

For the SEM clinician, it is important to assess the severity of ARinf in athletes in this ‘mild to moderate’ category of ARinf because this can: (1) influence the risk of medical complications during exercise after infection, which then guide clinical decision making in RTS following an ARinf, and (2) determine potential detrimental effects on exercise and sports performance post-infection. This IOC consensus group, by expert opinion, suggests that several parameters on clinical presentation (history and findings on clinical examination), as well as results of special investigations, can be useful indicators to stratify the severity of an ARinf in an athlete (table 4). We suggest that this clinical approach can be used in the initial assessment of athletes with ARinf and can form the basis of RTS decision making. However,

we recognise that validation of these indicators has not been established fully, and further research is needed.

**PRINCIPLES OF MANAGEMENT OF ARINF IN ATHLETES**

The two most common clinical syndromes of ARinf that an SEM clinician will manage routinely are the ‘predominantly’ upper ARinf syndromes of: (1) acute rhinitis/rhinosinusitis/rhinopharyngitis (‘common cold’, ‘coryza’, ‘viral upper respiratory infection’) and (2) acute rhinitis/rhinosinusitis/rhinopharyngitis with systemic symptoms/signs (‘influenza-like’, ‘influenza’ syndrome). In this section, we focus on the principles of management of these two clinical syndromes. Other clinical syndromes of upper ARinf (acute laryngitis and tracheobronchitis) are less common and lower ARinf syndromes in athletes are rare.

There are seven main principles of management of ARinf that SEM clinicians can consider.

**Clinical point/s: Seven principles of management of acute respiratory infections (ARinf) that Sport and Exercise Medicine clinicians can consider**

- ⇒ General non-pharmacological treatment to support recovery and the immune response.
- ⇒ Nutritional, immune or probiotic supplementation.
- ⇒ Pharmacological treatment of symptoms.
- ⇒ Antiviral agents (for specific cases).
- ⇒ Antibacterial agents (for specific cases).
- ⇒ Management of the athlete with suspected multiorgan involvement or other complications (if present).
- ⇒ Decisions to allow an athlete with an ARinf to return-to-sport, including the initial decision to resume training (return-to-participation), and the subsequent decision to return to full exercise/sport performance.

These principles will be briefly reviewed, but a detailed summary, including the specific treatment, the advice/administration dose, as well as evidence of the effect of the treatment and potential side effects unique to upper ARinf in athletes, is presented in table 5.

**General treatment to support recovery and the normal immune response**

**Rest/training reduction/restriction**

In an athlete presenting with ARinf, one of the first management decisions the SEM clinician will make is whether rest, training reduction or restriction of training is required during the acute phase of the ARinf. The following recommendations are based on the severity classification of the upper ARinf (table 4). In mild/moderate ARinf, normal daily activity is generally allowed. In most cases symptoms of ARinf resolve within 1–3 days, but it is advisable to perform a daily checklist before either starting or resuming exercise training (checklist 1: table 6).

In general, once localised symptoms have either resolved or are very mild, and if there are no items flagged in the checklist, the athlete can be advised to perform an exercise challenge test (self-administered field test by the athlete/coach/support staff or a laboratory test). In severe ARinf, bed rest is recommended until regional and systemic symptoms have resolved, and there is no evidence of active multiorgan involvement, after which normal daily activity is allowed. For severe ARinf, the athlete is advised to consult an SEM clinician who will perform a checklist before giving advice of resuming exercise training (checklist 2: table 6).



**Table 4** Indicators of the severity of an upper ARinf in athletes (history, physical examination and results of special investigations)

Indicator	Specific parameter	Severity		
		Mild	Moderate	Severe/complicated
Symptoms	▶ Predominant location of symptom/s*	▶ Predominantly upper respiratory symptoms without regional or systemic symptoms	▶ Predominantly upper or lower respiratory OR ▶ Regional symptoms (head, neck, chest) without systemic symptoms	▶ Multiple symptoms (upper or lower respiratory) with systemic symptoms AND/OR ▶ Other symptoms that may indicate multiorgan (non-respiratory) involvement
	▶ Type of symptom/s*	▶ Blocked/plugged nose, runny nose, sneezing, altered/loss sense of smell or taste, sinus pressure, sore/scratchy throat, hoarseness	▶ Lower respiratory tract symptoms (dry or wet/productive cough, difficulty in breathing†, fast breathing or shortness of breath†, chest pain associated with breathing or coughing) ▶ Other regional symptoms (headache and red, watery or scratchy eyes)	▶ Systemic symptoms (fever, chills, excessive fatigue, general muscle aches and pains, skin rash) ▶ Symptoms indicating other organ involvement for example, cardiac (chest pain, pressure or tightness, dizziness, palpitations/racing heart, shortness of breath†), gastrointestinal (severe abdominal pain, nausea, vomiting, diarrhoea and loss of appetite) or other organ systems
	▶ Symptom severity (European Position Paper on Rhinosinusitis and Nasal Polyps - EPOS 2020 statement) (VAS score 0–10) ‡	0–3	>3–7	>7–10
	▶ Symptom duration (time course over days from onset of symptoms)	▶ Short duration with early resolution (<3 days)	▶ More prolonged resolution of symptoms (3–7 days)	▶ Complicated with symptoms >7 day or symptoms that initially improve and then recur or become more severe
	▶ Total no of symptoms	<5	5–9	≥10
Clinical signs	▶ Respiratory system (evidence of complications)	▶ Predominantly upper/localised ARinf with no complications	▶ Upper/lower respiratory ARinf with some regional involvement/complications (ears, lymphadenopathy, trachea, bronchial)	▶ ARinf complicated by involvement of the lung parenchyma (pneumonia)
	▶ Symptoms and clinical signs of systemic illness§	▶ None	▶ Few, mild, transient (lasting ≤48 hours) signs of systemic illness ▶ Typical of non-specific acute phase reaction to infections	▶ Multiple and prolonged (lasting >48 hours) signs of systemic illness
	▶ Multiorgan involvement	▶ No clinical evidence of suspected or confirmed multiorgan (non-respiratory) involvement	▶ No clinical evidence of suspected or confirmed multiorgan (non-respiratory) involvement	Clinical evidence of suspected multiorgan (non-respiratory) involvement¶ ▶ Clinical evidence of confirmed multiorgan (non-respiratory) involvement
Laboratory tests for non-specific systemic involvement	▶ Inflammatory makers (CRP)	▶ Normal	▶ Normal or transient, mild elevation early in the disease	▶ Prolonged or significant increase
Pathogen identification (if indicated)	▶ Nasopharyngeal PCR ▶ Throat swab and culture ▶ Rapid antigen test ▶ Serum antibody tests (rise in antibodies)	▶ Generally, pathogen identification not indicated. ▶ Identification may be useful to control viral outbreaks.	▶ Pathogen identification may be indicated to enhance the quality of care and differentiate between viral and bacterial infections.	▶ Pathogen identification is recommended to enhance the quality of care and differentiate between viral and bacterial infections
Special investigations to exclude multiorgan involvement	▶ Types of investigations determined by clinical suspicion of organ system/s involved	▶ Generally special investigations are not indicated ▶ Normal if results are available	▶ Special investigations not routinely done – only indicated if clinical suspicion ▶ Normal or mild transient abnormality	▶ Special investigations are indicated to confirm multiorgan complication

\*Refer to online supplemental table S2: Symptoms of ARinf.  
 †Symptoms that can indicate lower respiratory tract involvement and/or cardiac involvement.  
 ‡VAS 0–10 (not troublesome to worst thinkable troublesome) (VAS >5 affects quality of life) from EPOS 2020 statement<sup>25</sup>  
 §Confirmed fever (core temperature ≥38°C), resting tachycardia, myalgia/arthritis, headache, malaise/excessive fatigue.  
 ¶Special investigations to exclude multiorgan involvement are recommended (see online supplemental table S4).  
 ARinf, acute respiratory infections; CRP, C reactive protein; VAS, Visual Analogue Scale.

Based on the outcome of the checklist, a decision can be made to conduct an exercise challenge test.

**General nutrition**

It is well known that general nutritional status influences both their susceptibility to infection and response to infection.<sup>80 81</sup> Thus, adequate energy availability as well as micro-and macro-nutrient intake are important for immune health in athletes with ARinf.<sup>80–82</sup>

**Hydration**

Maintenance of fluid intake during an ARinf is important to ensure that mucous membranes remain moist, to their defensive function and alleviate acute symptoms.<sup>82</sup> However, there is no evidence to support increasing fluid intake beyond the maintenance of normal hydration.

**Nasal saline irrigation**

Nasal saline irrigation may relieve symptoms of ARinf, but data are limited.

**Nutritional/immune supplements and/or probiotics**

The use of specific nutritional or immune supplements as well as probiotics for athletes with ARinf is common and has a high cultural influence and community support. In general, scientific evidence to support the widespread use of these agents is lacking (table 5). Some studies report that nutritional supplements have some benefit in reducing the duration of symptoms or the recovery time of ARinf and these include zinc,<sup>83 84</sup> Vitamin C and Vitamin D but only in vitamin deficient athletes. Although supplementation with herbal medicines is popular there is only low level evidence that some may be beneficial (table 5) including BNO1016, cineole and andrographis paniculata SHA-10 extract, pelargonium sidoides extract<sup>85 86</sup> and Echinacea.<sup>87</sup> Probiotics

**Table 5** A summary of the principles treatment of upper acute respiratory infection (ARInf) in athletes

Treatment/drug	Advice or administration/dose	Evidence of the effect of the treatment	Side effects or other considerations in athletes	Refs
1. General non-pharmacological treatment to support recovery and the immune response				
Rest, training reduction/restriction	<p>Mild/moderate ARInf:</p> <ul style="list-style-type: none"> <li>▶ Normal daily activity is allowed, and</li> <li>▶ Perform a daily checklist for contraindications to exercise, and</li> <li>▶ If the checklist for contraindications to exercise is normal, an exercise test (self-administered field test or a laboratory test) can be conducted</li> </ul> <p>Severe ARInf:</p> <ul style="list-style-type: none"> <li>▶ Bed rest with daily mobilisation is recommended until:                             <ul style="list-style-type: none"> <li>– Regional and systemic symptoms resolved and there is no evidence of active multiorgan involvement, <u>then</u></li> </ul> </li> <li>▶ Normal daily activity is allowed, <u>and</u></li> <li>▶ Perform a daily checklist for contraindications to exercise, <u>and</u></li> <li>▶ If the checklist for contra-indications to exercise is normal, an exercise test (laboratory test) can be conducted</li> </ul>	<ul style="list-style-type: none"> <li>▶ The effect of continuing regular, moderate- to high-intensity exercise in mild ARInf is not known</li> <li>▶ Benefits of regular exercise prior to ARInf:                             <ul style="list-style-type: none"> <li>– Strength of evidence affected by small study size, risk of bias, and heterogeneity in the populations studied contributing to the uncertainty of the findings</li> <li>– Regular, moderate-intensity exercise may have an effect on the prevention of ARInf</li> <li>– Exercise does not reduce the no of ARill episodes, proportion of participants experiencing at least one ARill, or the no of symptom days per episode of illness</li> <li>– Exercise reduced the severity of ARill symptoms and the number of symptom days during a follow-up period</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>▶ The main health risk to athletes is that moderate to high-intensity/duration exercise imposes additional physiological stress that may increase the risk of medical complications during exercise</li> </ul>	25 129
General nutritional support	<ul style="list-style-type: none"> <li>▶ Assess the general nutritional status of the athlete</li> </ul>	<ul style="list-style-type: none"> <li>▶ General and specific nutritional deficiencies are associated with compromised immune function</li> <li>▶ Meeting requirements of recommended intakes in carbohydrate and protein and avoiding deficiencies in nutrients and antioxidants is integral for optimal immune health</li> <li>▶ Athletes are recommended to follow a balanced diet to avoid a frank deficiency of a nutrient required for proper immune function</li> </ul>		80 82
Hydration (encouraging extra fluids)	<ul style="list-style-type: none"> <li>▶ Increase fluid intake during ARInf</li> </ul>	<ul style="list-style-type: none"> <li>▶ There is no evidence for or against the use of increased fluids in ARInf</li> <li>▶ There are no randomised controlled trials to determine the benefit or harm from extra fluids in ARInf</li> </ul>	<ul style="list-style-type: none"> <li>▶ In lower respiratory tract infections, possible harmful effects of excessive fluid intake fluids might be a dilution of the blood sodium concentration, leading to headache, confusion and seizures</li> </ul>	130
Nasal saline irrigation		<ul style="list-style-type: none"> <li>▶ Possibly relieves the symptoms of upper ARInf (mainly in children)</li> <li>▶ One trial showed a significant reduction in the use of decongestant medication when using saline irrigation</li> </ul>		25 131
Hot, humidified air (steam) inhalation	<ul style="list-style-type: none"> <li>▶ Inhalation of hot, humidified air (eg, Rhino Therm device)</li> </ul>	<ul style="list-style-type: none"> <li>▶ Current evidence does not show any benefits or harms from the use of heated, humidified air for the treatment of upper ARInf</li> <li>▶ No clear benefit or harm.</li> </ul>		132
2. Nutritional, immune, or probiotic supplementation				
Vitamin C	<ul style="list-style-type: none"> <li>▶ Regular vitamin C supplementation</li> </ul>	<ul style="list-style-type: none"> <li>▶ Regular vitamin C supplementation has a modest but consistent effect in reducing the duration of upper ARInf symptoms</li> <li>▶ It may be worthwhile to test if athletes with upper ARInf will benefit from therapeutic vitamin C—on an individual basis</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	133
	<ul style="list-style-type: none"> <li>▶ High dose vitamin C supplementation after the onset on ARInf</li> </ul>	<ul style="list-style-type: none"> <li>▶ High doses of vitamin C administered after the onset of upper ARInf symptoms, showed no consistent effect on the duration or severity of symptoms</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	133
Vitamin D	<ul style="list-style-type: none"> <li>▶ Vitamin D supplementation as treatment of ARInf</li> </ul>	<ul style="list-style-type: none"> <li>▶ There are few studies investigating whether vitamin D supplementation is effective treatment for ARInf</li> <li>▶ Obtaining serum 25 (OH) D levels in athletes with repeated viral respiratory infections, especially COVID-19, could help in the detection and treatment of vitamin D deficiency and potentially decrease recovery time and improve outcome (no clear evidence)</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	134
Zinc	<ul style="list-style-type: none"> <li>▶ Zinc acetate/gluconate</li> </ul>	<ul style="list-style-type: none"> <li>▶ Zinc administered as zinc acetate or zinc gluconate lozenges (dose of <math>\geq 75</math> mg/day) and taken within 24 hours of onset of symptoms significantly reduces the duration of upper ARInf</li> <li>▶ Advisable to use it at this dose throughout the upper ARInf</li> <li>▶ Prophylactic zinc supplementation - currently no firm recommendation can be made because of insufficient data</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	25 135

Continued

Table 5 Continued

Treatment/drug	Advice or administration/dose	Evidence of the effect of the treatment	Side effects or other considerations in athletes	Refs
Echinacea	▶ Various echinacea products	<ul style="list-style-type: none"> <li>▶ Quality of the evidence is low or very low</li> <li>▶ Echinacea products have not been shown to provide benefits for treating upper ARinf</li> <li>▶ Clinical trials do show some non-significant trends but effects are of questionable clinical relevance</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider anti-doping regulations in athletes</li> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	25
Herbal medicine (excluding Echinaceae)	▶ Various herbal medicines	<ul style="list-style-type: none"> <li>▶ Quality of the evidence is low or very low</li> <li>▶ Herbal medicines such as BNO1016, cineole and andrographis paniculata SHA-10 extract may shorten the duration of symptoms of upper ARinf</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider anti-doping regulations in athletes</li> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	25 136
▶ Probiotics	▶ Various probiotic formulations	<ul style="list-style-type: none"> <li>▶ Quality of the evidence is low or very low</li> <li>▶ May help reduce the no of and the mean duration of upper ARinf</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider anti-doping regulations in athletes</li> <li>▶ Consider potential contamination of nutritional supplements with substances that may result in violation of anti-doping rules</li> <li>▶ Consider using products that undergo regular batch testing</li> </ul>	137
<b>3. Pharmacological treatment of symptoms</b>				
Analgesics	▶ Paracetamol (Acetaminophen)	▶ Paracetamol may help relieve nasal obstruction and rhinorrhoea but does not appear to improve other cold symptoms (including sore throat, malaise, sneezing and cough)		25
Non-steroidal anti-inflammatory drugs (NSAIDs)	▶ Various NSAID's	<ul style="list-style-type: none"> <li>▶ NSAIDs do not significantly reduce the total symptom score, or duration of upper ARinf</li> <li>▶ For outcomes related to the analgesic effects of NSAIDs (headache, ear pain and muscle and joint pain) NSAIDs produce significant benefits</li> <li>▶ For respiratory symptoms, cough and nasal discharge scores are not improved, but the sneezing score is significantly improved</li> </ul>	<ul style="list-style-type: none"> <li>▶ There is no evidence of a significantly increased frequency of adverse effects in the NSAID treatment groups</li> <li>▶ NSAID's can lead to gastric side effects, may increase risk of bleeding, can have renal side effects</li> <li>▶ NSAIDS can mask symptoms, which can lead to a false positive perception of the clinical status of an athlete</li> </ul>	25
Mucolytics	▶ Acetylcysteine and carbocysteine	▶ Acetylcysteine and carbocysteine have limited efficacy in the treatment of ARinf (data mainly in children) (few studies)		138
Corticosteroids	▶ Systemic corticosteroids in acute sinusitis	▶ There is limited evidence to indicate that oral corticosteroids in combination with antibiotics may be modestly beneficial for short-term relief of symptoms in acute sinusitis	▶ Consider anti-doping regulations in athletes	139
	▶ Systemic corticosteroids for acute sore throat	▶ Oral or intramuscular corticosteroids, in addition to antibiotics, increase the likelihood of both resolution and improvement of pain in participants with sore throat	▶ Consider anti-doping regulations in athletes	140 141
	▶ Intranasal corticosteroids	▶ Current evidence does not support the use of nasal corticosteroids for symptomatic relief in upper ARinf		25
Decongestants	▶ Nasal decongestants	▶ Multiple doses of nasal decongestants may have a small positive effect on subjective measures of nasal congestion in adults with upper ARinf	▶ Consider anti-doping regulations in athletes	142
Antitussive agents	▶ Various over-the counter cough medications	▶ There is no good evidence for or against the effectiveness of OTC medications in acute cough	▶ Consider anti-doping regulations in athletes	143
Antihistamines	▶ Various anti-histamine medications	<ul style="list-style-type: none"> <li>▶ Antihistamines have a limited short-term (days 1 and 2 of treatment) beneficial effect on severity of overall symptoms in adults but not in the mid to long term</li> <li>▶ There is no clinically significant effect on nasal obstruction, rhinorrhoea or sneezing</li> </ul>	▶ Sedation was more common with sedating antihistamines	144
Combination drugs	▶ Antihistamine-decongestant-analgesic combinations	▶ There is some general benefit in adults and adolescents, but they should be weighed against the risk of adverse effects	<ul style="list-style-type: none"> <li>▶ Consider anti-doping regulations in athletes</li> <li>▶ Not recommended for children</li> </ul>	145 146
Anticholinergics	▶ Intranasal Ipratropium bromide	▶ There is evidence for a consistent reduction of rhinorrhoea, but not nasal congestion	▶ Side effects are mild (nasal dryness, blood-tinged mucus, and epistaxis)	147
<b>4. Antiviral agents</b>				
Neuraminidase inhibitors	▶ Oseltamivir or zanamivir	<ul style="list-style-type: none"> <li>▶ Influenza A and B: Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children</li> <li>▶ Oseltamivir and zanamivir can be used as prophylaxis to reduce the risk of developing symptomatic influenza in exposed athletes</li> </ul>	▶ There is a low risk of adverse effects with oseltamivir, including nausea, vomiting, psychiatric effects and renal events in adults (vomiting in children)	148
<b>5. Antibacterial agents</b>				

Continued

Table 5 Continued

Treatment/drug	Advice or administration/dose	Evidence of the effect of the treatment	Side effects or other considerations in athletes	Refs
Antibiotics	▶ General antibiotic use for upper ARinf (rhinitis, rhinosinusitis)	<ul style="list-style-type: none"> <li>▶ Consider antibiotic use preferably only in confirmed bacterial infections</li> <li>▶ The place for antibiotics is very limited and they should only be given in situations pointing to severe disease with symptoms and signs such as high fever, double sickening, severe pain and elevated ESR</li> </ul>	<ul style="list-style-type: none"> <li>▶ Widespread antibiotic use causes antibiotic resistance</li> <li>▶ Consider potential side effect of antibiotics in athletes (eg, tendinopathies with fluoroquinolones, and cardiac arrhythmias with azithromycin)</li> </ul>	25 149 150
	▶ Antibiotics for acute pharyngitis (adults and children)	<ul style="list-style-type: none"> <li>▶ Consider antibiotic use preferably only in confirmed bacterial infections</li> <li>▶ Antibiotics reduced the number of people still experiencing headache on the third day of illness</li> <li>▶ Antibiotics probably reduced the number of people with sore throat after 3 days and 1 week, as well as rheumatic fever within 2 months in communities where this complication is common</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential side effect of antibiotics in athletes (eg, tendinopathies with fluoroquinolones, and cardiac arrhythmias with azithromycin)</li> </ul>	151
	▶ Antibiotics for acute laryngitis (adults)	<ul style="list-style-type: none"> <li>▶ Consider antibiotic use preferably only in confirmed bacterial infections</li> <li>▶ Antibiotics do not appear to be effective in treating acute laryngitis when assessing objective outcomes</li> </ul>	<ul style="list-style-type: none"> <li>▶ Consider potential side effect of antibiotics in athletes (eg, tendinopathies with fluoroquinolones, and cardiac arrhythmias with azithromycin)</li> </ul>	152

Therapy.  
ARinf, acute respiratory illness; ESR, erythrocyte sedimentation rate.

may help reduce the number of and the mean duration of upper ARinf,<sup>88</sup> but the quality of the evidence is low. In summary, evidence for these therapies is generally of low quality, remains mixed and further studies are required.

**Pharmacological treatment of symptoms**

Treatment of symptoms is an important component of the clinical care of athletes with ARinf. Rhinorrhoea may impair athletes’ well-being and physical performance and swollen mucous membranes in the nasopharynx may give rise to obstruction and predispose athletes to secondary otitis media and/or sinusitis. There are several options for pharmacological treatment of symptoms of ARinf in athletes including analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), mucolytics, corticosteroids, decongestants, antitussive agents, antihistamines, and combination drugs. Options for the pharmacological treatment of symptoms, and evidence for using these medications during the acute phase of upper ARinf, is summarised in table 5.

These treatments are frequently available as over-the-counter drugs in most countries, and therefore, are not well controlled by SEM clinicians and may cause side effects in athletes and can lead to doping violations. For example, NSAID’s can lead to gastric side effects, may increase risk of bleeding, can have renal side effects, and by masking symptoms can lead to a false positive perception of the clinical status of an athlete.

**Antiviral agents**

Antiviral treatment is available only for influenza viruses. SEM clinicians should be aware of the prevailing viral epidemics and can confirm influenza virus infection by PCR when suspected. In cases of confirmed influenza infection, antiviral treatment with oseltamivir or zanamivir should be started soon after the onset of the symptoms,<sup>89</sup> but side effects of these drugs must be considered (table 5). If an athlete has been in close contact with influenza virus, prophylaxis treatment can be considered. Point-of-care-testing enables prophylaxis with oseltamivir for those predisposed to influenza virus infections, for example, living in same household or travelling in the same flight or carpool (<https://www.cdc.gov/>). Isolation of infected team members should be initiated after the onset of symptom/s and continued for 3–4 days, that is, the most infectious period.<sup>90</sup>

**Antibacterial agents**

Details about specific antibacterial (antibiotic) therapy for bacterial infections is beyond the scope of this consensus. In general, the place for general antibacterial agent use in athletes with upper ARinf is limited. Although antibiotics are widely used in the treatment of uncomplicated viral ARinf among athletes, they are not effective against viruses and can have negative side effects<sup>91</sup> (table 5). It is recommended that antibiotic treatment is only considered in cases where there is clear identification of the (detected or suspected) infectious agent. In some cases of acute tonsillitis with an exudate, antibiotic treatment may be indicated if there is a strong clinical suspicion of a bacterial infection, but identification of a bacterial cause is still preferable. In most cases presenting as acute pharyngitis, a clinical diagnosis of a bacterial infection is almost impossible. Although antibiotics are only effective against bacteria, they are sometimes used to prevent bacterial superinfections (and re-infections).

**Management of the athlete with suspected multiorgan involvement or other complications**

An ARinf can lead to a variety of medical complications, even fatal, because of multiorgan involvement. Potential respiratory system complications or complications in other organs and organ systems (online supplemental table S1), and special investigations to diagnose these complications (online supplemental table S4) can be considered. Although these complications are rare, it is important that the SEM clinician considers them, particularly in athletes presenting with moderate or severe ARinf. Diagnostic work-up and management of athletes with suspected multiorgan involvement should be conducted in conjunction with appropriate specialist colleagues.

**RTS CONSIDERATIONS FOLLOWING ARINF IN ATHLETES Terminology and key concepts related to the RTS decision**

Traditionally, the point at which an athlete fully recovered from an injury or illness and returned to full participation at the pre-injury or illness level has been termed either return-to-play (RTP) or RTS. The first key concept is that the term RTP has mostly been used in the context of team rather than individual sports. In this consensus document, we agreed to use the term RTS because this term is more inclusive, is relevant to all sports,



**Table 6** Checklists before starting or resuming exercise training in an athlete with acute respiratory infection (ARinf)

Checklist 1: A checklist self-administered by the athlete or administered by the coach/support staff before exercise training starts or continues after an ARinf. Generally recommended in cases of mild ARinf or asymptomatic ARinf.		
Checklist		Yes No
Question 1: Do you have any of the following symptoms at rest?	Fever (raised body temperature)	
	Chills	
	Excessive fatigue/tiredness	
	General muscle aches and pains	
	Breathing difficulty, including fast breathing or shortness of breath	
	Chest pain, chest pressure or chest tightness	
	Dizziness, palpitations/racing heart (faster than normal) at rest	
	Moderate to severe dry or wet cough	
	Severe headache	
	Persistent and/or severe nose/throat symptoms (eg, blocked/plugged nose, runny nose, sinus pressure, sore/scratchy throat, or hoarseness)	
	Persistent abdominal symptoms after the infection (eg, abdominal pain, nausea, vomiting, diarrhoea)	
Just 'not feeling well enough' to exercise		
Question 2: Do you have any of the following risk factors that are associated with more severe ARinf?	History of heart disease, history of blood vessel disease, history of lung disease including asthma, history of cancer, history of diabetes mellitus, history other chronic diseases, history of immune diseases or reduced immunity, obesity, or high body mass index (BMI >30)	
Outcome of checklist 1: The athlete can continue with a self-administered exercise challenge test if: ▶ the athlete answered 'No' to any symptoms (question 1), and 'No' to any risk factors (question 2) If the athlete answered 'No' to any symptoms (question 1), but 'Yes' to risk factors (question 2), the athlete can cautiously continue with a self-administered exercise challenge test provided: ▶ Chronic conditions are well controlled ▶ A healthcare practitioner provided clearance in cases of chronic conditions that are not controlled, or if this is not known It is recommended that the athlete consult with a healthcare practitioner to re-assess the severity of the ARinf, and be fully evaluated if: ▶ athlete answered 'No' to any symptoms (question 1)		
Checklist 2: A checklist performed by the Sport and Exercise Medicine (SEM) clinician before advising an athlete to start or continue exercise after an ARinf.		
Checklist		Yes No
Question 1: Does the athlete have any of the following symptoms at rest?	Fever (raised body temperature)	
	Chills	
	Excessive fatigue/tiredness	
	General muscle aches and pains	
	Breathing difficulty, including fast breathing or shortness of breath	
	Chest pain, chest pressure, or chest tightness	
	Dizziness, palpitations/racing heart (faster than normal) at rest	
	Moderate to severe dry or wet cough	
	Severe headache	
	Persistent sand/or evere nose/throat symptoms (eg, blocked/plugged nose, runny nose, sinus pressure, sore/scratchy throat, or hoarseness)	
	Persistent abdominal symptoms after the infection (eg, abdominal pain, nausea, vomiting, diarrhoea)	
Question 2: Does the athlete have any of the following clinical signs at rest?	Fever (Temperature >38°C) or elevated body temperature	
	Abnormal vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation on pulse oximetry—if indicated)	
	Abnormal clinical signs during a systematic examination of organ systems (NB: cardiovascular, respiratory, abdominal, neuromuscular) indicative of ongoing local/systemic infection or significant organ dysfunction	
Question 3: Does the athlete have any of abnormal special investigation results?	Abnormalities in special investigations conducted to assess any organ systems (at rest): results need to be interpreted on an individual basis an in the clinical context	
Question 4: Does the athlete have any of the following risk factors that are associated with more severe ARinf?	History of heart disease, history of blood vessel disease, history of lung disease including asthma, history of cancer, history of diabetes mellitus, history other chronic diseases, history of immune diseases or reduced immunity, obesity, or high body mass index (>30)	
Outcome of checklist 2: An exercise challenge test can be performed to assess the response to exercise if: ▶ there are no symptoms and abnormal clinical signs or abnormal special investigations in the checklist ('No' to all questions 1-3) ▶ any modifiable risk factors for more severe diseases (eg, chronic diseases) are not present ('No' to question 4) or are present ('Yes' to question 4) but well controlled The attending SEM clinician or other qualified health professional can decide on further assessment and treatment of the athlete on an individual basis if: ▶ there are symptoms (present and are severe or getting worse over time) (Any 'Yes' to question 1) ▶ there are abnormal clinical signs or abnormal special investigations in the checklist (Any 'Yes' to questions 2-3) ▶ any modifiable risk factors for more severe diseases (eg, chronic diseases) are present ('Yes' to question 4) but not well controlled		

## Consensus statement

and was the recommended term by a 2016 consensus statement on RTS after injury.<sup>92</sup>

A second important concept is that RTS must be viewed as a continuum rather than a single time point at the end of recovery from an injury or illness. In the 2016 consensus on RTS, three time points of RTS on a continuum were suggested: return to participation, RTS and return to performance.<sup>92</sup> These elements emphasise a graded, outcome-based progression to RTS that can be applied for any sport. For the purposes of this consensus, the following terminology and definitions will be used: (1) Return-to-participation (alternatively return-to-training) is defined as 'the time point (day from onset of illness) when an athlete resumes with the first training/exercise session after an ARInf', and (2) RTS is defined as 'the time point (day) when an athlete has progressed to the same pre-illness level of sport participation (sport performance) or exercise type, intensity, duration and frequency (exercise performance)'. The RTS process may progress rapidly from return-to-participation to RTS (from 1 day to a few days) or evolve gradually and progressively over a longer time (few days to weeks). The rate of progression depends on several factors, including the severity of the ARInf, evidence of associated medical complications in other organ systems, normal responses to progressive increases in training load, and the presence of other modifiers that are part of a complex decision-making process and framework for RTS decisions.

The third concept is that the consensus group broadly adopts the Strategic Assessment of Risk and Risk Tolerance (StARRT) framework for RTS decisions.<sup>93</sup> The principle of the StARRT framework is that the RTS decision making process involves three important steps: (1) assessment of health risk, (2) assessment of activity risk, and (3) assessment of risk tolerance through modifiers such as the need/desire for an elite athlete to progress to RTS more rapidly.<sup>93</sup> The final general concept is that, as for injuries, the final clearance to RTS after an ARInf is a shared-decision-making process that considers physical, psychological and social factors (biopsychosocial model).<sup>92</sup>

### The scientific basis for RTS decisions after an ARInf in athletes

Even though the RTS clinical decision-making process is very common and important for the SEM clinician, there is little research available to support a sound scientific approach to RTS after an ARInf. Historically, RTS decisions following an ARInf were guided by expert opinion to follow the 'neck check' rule.<sup>94-95</sup> Subsequently, other RTS guidelines have been published,<sup>96-97</sup> including several recently published expert opinions that mainly focused on cardiovascular concerns following SARS-CoV-2 infection in athletes.<sup>62-98-103</sup> These 'expert opinions' were initially based on no data to support the guidelines, but recently some data became available.<sup>104-106</sup> The more recent guidelines were only for athletes with SARS-CoV-2 infection and did not focus on all ARInf (irrespective of the pathogen responsible for the ARInf). They have not consistently considered the key concepts and the three steps in the RTS decision making process, as discussed above.

A systematic review with a meta-analysis was commissioned for this consensus statement to evaluate the scientific evidence for RTS decision making after ARill. Specifically, the aims were to determine the days until RTS after ARill, % of time loss ARill (ARill resulting in >1 day lost from training/competition), and symptom duration (days) of ARill in athletes.<sup>27</sup> This review included published studies up to August 2021 before any data on SARS-CoV-2 in athletes became available, identified a total of 54 studies representing 31 065 athletes. Only four studies reported

actual days until RTS following ARill, ranging from 0 to about 8 days. The mean symptom duration for all ARill was 7 days. Notably the pooled frequency (%) of ARill resulting in >1 day lost from training/competition was ~20% indicating that in most cases athletes continued training or competing. Consequently, athletes and coaches can be reassured that most ARill either do not interfere with training, or only result in a short period of interrupted or no training. This is consistent with the observation that most (>80%) ARInf are mild, self-limiting and of short duration. Future studies are needed to obtain detailed clinical, laboratory and specific pathogen data on ARInf to customise RTS. The remaining 20% of athletes who have more moderate or severe disease may be at increased risk of adverse medical events during exercise when they RTS.

### Guidelines for RTS of an individual with ARInf

We recommend a stepwise RTS clinical decision-making process that can be applied to all athletes with ARInf, irrespective of the pathogen involved. The recommendations are based on the StARRT framework<sup>93</sup> and involves the following four stepwise assessments: (1) severity of the ARInf based on symptoms, (2) health risk based on history, clinical assessment and special investigations (where indicated), (3) activity risk (risk of adverse medical event during exercise) and (4) risk tolerance. This stepwise assessment and decision making algorithm is summarised in [figure 2](#).

#### Step 1: assessment of infection severity based on symptoms


The purpose of the initial assessment of ARInf severity, based on symptoms, is to determine the degree to which detailed subsequent assessments of risk, activity risk and risk tolerance should be undertaken. The principle is that not all athletes with ARInf require a full medical assessment and a battery of special investigations. For example, asymptomatic and minor ARInf are successfully self-managed by many athletes and coaches. Recently, during the COVID-19 pandemic, most guidelines recommend a RTS decision tree should be based on an initial determination of severity of ARInf.<sup>62-98-103</sup> However, there is no consensus on a severity classification to use in athletes with ARInf. We propose criteria to classify the severity of ARInf in athletes based on their initial presenting symptoms into four categories: (1) asymptomatic ARInf (positive test or high risk of exposure but no symptoms), (2) mild ARInf, (3) moderate ARInf and (4) severe ARInf ([table 4](#): symptoms). Based on this classification, further decision making on RTS (steps 2-4) is recommended ([figure 2](#)).

#### Step 2: assessment of health risk ('tissue health')

The purpose of the assessment of risk is to determine the risk of an adverse medical event when exercise continues during an ARInf or resumes after an ARInf. The elements of the assessment are the medical history, findings on a clinical assessment, and results of selected special investigations. It is criteria-based and the need for the elements of the assessment are based on the severity of the ARInf, and individual athlete risk factors associated with more severe ARInf.

#### Asymptomatic and mild ARInf

In the case of athletes with asymptomatic or mild ARInf, we recommend that the assessment of health risk be self-administered or administered by the coach/support staff. Athletes with asymptomatic or mild ARInf are encouraged to complete a daily checklist ([table 6](#): checklist 1) before proceeding to step 2 (assessment of activity risk). If no chronic conditions or no symptoms in



**Figure 2** Summary of the RTS clinical decision-making process for athletes with acute respiratory infection (Arinf). \* Reassignment of severity categories can take place after clinical assessment and special investigations (criteria in table 4). Strategic Assessment of Risk and Risk Tolerance framework for return-to-play decision making.<sup>93</sup> CPET, cardiopulmonary exercise testing; CRP, C reactive protein; RTS, return-to-sport; SEM, sport and exercise medicine.

the checklist are present, the athlete can continue with a self-administered or coach-administered exercise challenge test. If chronic conditions or symptoms in the checklist are present, it is recommended that the athlete consult with a physician or healthcare professional to reassess the severity of the ARinf and be fully evaluated for moderate or severe ARinf.

### Moderate or severe ARinf

The RTS process for moderate or severe ARinf should be under the care of a physician or other healthcare professional. A more detailed history and a full clinical assessment can be considered before return-to-participation for all athletes with moderate ARinf. In cases of severe ARinf a more detailed history and a full clinical assessment by a physician is strongly recommended. Special investigations/laboratory tests are generally not required for athletes with mild ARinf (except on an individual basis for athletes with risk factors that are associated with more severe ARinf). Basic laboratory tests for non-specific systemic involvement (eg, CRP and FBC) can be considered in athletes with moderate ARinf, while more extensive special investigations/laboratory tests are recommended in severe ARinf. The types of investigations are determined by the suspected organ

involvement (online supplemental table S4). On completion of the risk assessment, the physician can re-assign the risk category (figure 2).

After the risk assessment, as for asymptomatic or mild ARinf, we recommend that the physician or healthcare professional perform a checklist before an athlete performs the exercise challenge test (table 6: checklist 2). If no abnormalities are identified by these checklists, the athlete can undergo a supervised laboratory-based exercise challenge test.

### Step 3: assessment of activity risk (risk of adverse medical event during exercise)

The assessment of activity involves: (1) determining the physiological demands that exercise/sport will place on organ systems when training resumes and (2) a continual assessment of the response of the athlete as training progresses. The first step in the assessment of activity risk is to perform a graded exercise challenge test. The specific outcomes are to determine if there are any abnormal symptoms, clinical signs or laboratory-measured responses to the exercise challenge (during, immediately after or for 24 hours after the test).

**Box 1 Guidelines to performing an exercise challenge test in an athlete after an acute respiratory infection (ARinf)**

1. Self-administered or coach/support staff administered exercise challenge test
  - ⇒ This test can be administered by the athlete themselves or a coach/trainer/support staff.
  - ⇒ Always start by performing a pre-exercise checklist based on symptoms (table 6—checklist 1).
  - ⇒ Select a suitable field-based test (eg, a standard warm-up exercise session, standard walk/jog/cycle/swim).
  - ⇒ Perform the exercise test as follows:
    - ⇒ Choose a moderate exercise intensity (60%–70% of normal exercise intensity).
    - ⇒ Assess your response (how you feel) after 10–20 min of exercise.
    - ⇒ Monitor for symptoms during exercise.
    - ⇒ Discontinue the exercise challenge test if any of the following symptoms develop during exercise (excessive fatigue/tiredness, shortness of breath/breathlessness, chest pain/discomfort, dizziness, palpitations/racing heart (faster than normal, eg, on heart rate monitor), muscle/joint pain, higher level of effort for the same past exercise load and ‘not feeling well’)—consult with a medical doctor if any these symptoms develop.
    - ⇒ Monitor for the same symptoms as above (with the addition of very dark brown/red urine after exercise) immediately after exercise and 24 hours after exercise - consult with a medical doctor if any of these symptoms develop.
2. Laboratory-based exercise challenge test
  - ⇒ The laboratory test is administered by a health professional in a laboratory setting under supervised conditions.
  - ⇒ The health professional first performs the pre-exercise checklist based on symptoms, clinical signs and the results of special investigations (table 6—checklist 2).
  - ⇒ Select a suitable standardised laboratory test (eg, Modified Bruce protocol).
  - ⇒ Select the special investigations to be performed before, during and/or after the exercise challenge test.
    - ⇒ Rating of perceived exertion (RPE), rating of perceived breathlessness (RPB), heart rate and blood pressure response to exercise—recommended.
    - ⇒ Exercise ECG: moderate ARinf (based on clinical suspicion); severe ARinf (recommended).
    - ⇒ Pre-exercise and postexercise pulmonary function testing (decision based on clinical suspicion).
    - ⇒ Other special investigations—based on clinical suspicion.
  - ⇒ Perform the exercise challenge test as follows:
    - ⇒ Perform measurements at rest and start at the first stage of the exercise test protocol.
    - ⇒ Monitor for the development of abnormal symptoms during exercise at the end of each stage and discontinue the exercise test if any of the following symptoms develop (excessive fatigue/tiredness, shortness of breath/breathlessness, chest pain/discomfort, dizziness, palpitations/racing heart, excessive cough, wheeze, stridor, muscle/joint pain, higher level of effort for the same past exercise load and ‘not feeling well’).
    - ⇒ Monitor for the development of abnormal clinical signs during exercise at the end of each stage and discontinue

Continued

**Box 1 Continued**

- the exercise test if any of the following clinical signs develop (abnormal heart rate and blood pressure response, very high respiratory rate, inappropriately high RPE and RPB).
- ⇒ Monitor for the same symptoms, signs and for a prolonged heart rate recovery after exercise.
- ⇒ Monitor for abnormalities when special investigations (ECG, pulmonary function testing) are done during and after exercise.
- ⇒ Monitor for symptoms (above), with the addition of dark urine in the 24 hours after exercise.
- ⇒ Re-assess the athlete if any abnormal symptoms, clinical signs or special investigations develop or are evident during, immediately after or 24 hours after exercise.

*Asymptomatic and mild ARinf*

In cases of asymptomatic or mild ARinf, the exercise challenge test may be a sport-specific field (or laboratory) test that is conducted either by the athlete, or in conjunction with the coach/strength and conditioning staff (box 1).

After the exercise challenge test, the athlete (coach or trainer) must perform a postexercise checklist (table 7: checklist 3). If there are no abnormal responses during or after exercise, the athlete can progress with increased training load (increased training frequency, intensity and duration), while self-monitoring for the same abnormal responses during and after each exercise training session (table 7: Checklists 3).

If there are abnormal responses during or after the exercise challenge test, or any subsequent exercise sessions at higher training loads, then the athlete should stop training and consult a physician or healthcare professional who will reassess the ARinf.

*Moderate or severe ARinf*

In cases of moderate ARinf, the recommendation is to either advise that the athlete performs a self-administered exercise challenge test or performs an exercise challenge test in a laboratory setting under supervision of trained medical staff (box 1). The choice would be based on the decision by the physician or healthcare professional. In cases of severe ARinf, the recommendation is to perform an exercise challenge test in a laboratory setting under supervision of trained medical staff (box 1). In moderate or severe ARinf either the athlete or the physician or qualified healthcare professional must complete a checklist (table 7: checklist 3 for the athlete, and checklist 4 for the SEM clinician) to determine whether the response to the exercise challenge test was normal. If there are no abnormal responses during or after exercise, the athlete can progress with increased training load (increased training frequency, intensity and duration), while self-monitoring for the same abnormal responses during and after each session (table 7: checklists 3 and 4). Again, if there are abnormal responses during or after the exercise challenge test, or any subsequent exercise sessions at higher loads, then the athlete should stop training and a physician or healthcare professional should re-assess the ARinf.

Assessment of activity risk is ongoing as training load progresses from return-to-participation/training to full return-to-performance and is mainly outcome based. The main outcome is to not only monitor for any abnormal responses to the exercise test (during, immediately after or 24 hours after the test), but also to determine if: (1) the athlete’s adaptation to training is as



**Table 7** Checklists after an exercise/training session before the training load (intensity, duration, frequency) can increase in athletes with an acute respiratory infection (ARinf)

**Checklist 3: A checklist self-administered by the athlete or administered by the coach/support staff after an exercise/training session before the training load (intensity, duration, frequency) can increase. Generally recommended in cases of mild ARinf or asymptomatic ARinf.**

	Checklist	Yes	No
Question 1: Do you have any of the following symptoms during or immediately after my exercise/training session?	Chest pain, discomfort or pressure		
	Excessive shortness of breath or breathlessness		
	Palpitations, racing heart, irregular heartbeat		
	Dizziness during exercise		
	Excessive fatigue or tiredness		
	A feeling of a higher level of effort for the same past exercise load		
	Muscle/joint pain		
	Just 'not feeling well' during exercise		
Question 2: Do you have any of the following symptoms 24 hours after my exercise/training session?	Chest pain, discomfort or pressure		
	Excessive shortness of breath or breathlessness		
	Palpitations, racing heart, irregular heartbeat		
	Persistent dizziness during exercise		
	Excessive fatigue or tiredness		
	A feeling of a higher level of effort for the same past exercise load		
	Muscle/joint pain		
	Just 'not feeling well' after exercise		
	Very dark brown/red urine		

Checklist 3 must be performed after each training/exercise session until full level of training and performance (to pre-infection level) is reached.

The athlete can increase the training load (intensity, duration and frequency) at the next exercise/training session if:

- ▶ no symptoms in the checklist are present (Any 'No' to questions 1 and 2)

It is recommended that the athlete consult with a healthcare professional to re-assess the severity of the ARinf, and be fully evaluated if:

- ▶ symptoms in the checklist are present (Any 'Yes' to questions 1 and 2)

**Checklist 4: A checklist performed by the Sport and Exercise Medicine (SEM) clinician before advising an athlete with an ARinf to increase the training load (intensity, duration, frequency)**

	Checklist	Yes	No
Question 1: Does the athlete have any of the following symptoms during or immediately after an exercise/training session?	Chest pain, discomfort or pressure		
	Excessive shortness of breath or breathlessness		
	Palpitations, racing heart, irregular heartbeat		
	Dizziness during exercise		
	Excessive fatigue or tiredness		
	A feeling of a higher level of effort for the same past exercise load		
	Muscle/joint pain		
	Just 'not feeling well' during exercise		
Question 2: Does the athlete have any of the following abnormal clinical signs or abnormal special investigations during or immediately after an exercise/training session?	An abnormal cardiovascular response to exercise: heart rate, blood pressure, rating of perceived exertion and rating of perceived breathlessness, heart rate recovery		
	An abnormal respiratory response to exercise: excessive shortness of breath (very high respiratory rate), excessive cough, wheeze, stridor		
	An abnormal exercise electrocardiogram (eg, arrhythmias, ischaemic changes, other ST or T-wave abnormalities)		
	An abnormal pre-post exercise pulmonary function test (eg, evidence of significant bronchoconstriction)		
	Any other abnormal responses to exercise (based on other special investigations)		
Question 3: Does the athlete have any of the following symptoms 24 hours after an exercise/training session?	Chest pain, discomfort or pressure		
	Excessive shortness of breath or breathlessness		
	Palpitations, racing heart, irregular heartbeat		
	Persistent dizziness during exercise		
	Excessive fatigue or tiredness		
	A feeling of a higher level of effort for the same past exercise load		
	Muscle/joint pain		
	Just 'not feeling well' after exercise		
	Very dark brown/red urine		
Question 4: Does the athlete have any of the following abnormal clinical signs or abnormal special investigations 24 hours after an exercise/training session?	Abnormalities in special investigations conducted to assess any organ system response 24 hours post exercise (eg, post exercise creatine kinase activity, renal function) (results need to be interpreted on an individual basis)		

Continued

Table 7 Continued

**Checklist 4: A checklist performed by the Sport and Exercise Medicine (SEM) clinician before advising an athlete with an ARinf to increase the training load (intensity, duration, frequency)**

## Outcome of checklist 4:

Checklist 4 must be performed after each training/exercise session until full level of training and performance (to pre-infection level) is reached.

The athlete can be advised to increase the training load (intensity, duration and frequency) at the next exercise/training session if:

- ▶ no symptoms, abnormal clinical signs or abnormal special investigations in the checklist are present ('No' to all questions 1-4)
- The attending SEM clinician or other qualified health professional can decide on further assessment and treatment of the athlete on an individual basis if:
  - ▶ any symptoms, abnormal clinical signs or abnormal special investigations in the checklist are present (Any 'Yes' to questions 1-4)

expected, or (2) there are other barriers to progression such as fatigue, soreness, or musculoskeletal injury. In general, a more rapid progression, with no abnormal responses, is likely in cases of asymptomatic ARinf or mild ARinf, while the rate of progression may be slower in cases of moderate/severe ARinf.

**Step 4: assessment of risk tolerance**

Continuous assessment of risk tolerance modifiers (eg, internal (self) or external pressures on the athlete, travel, timing of competitions, masking of symptoms, and conflict(s) of interest) is performed as the athlete progresses from return-to-participation to return-to-performance, completing the final RTS decision.

The final RTS decision is taken only when the risk assessments (steps 2 and 3) are below an acceptable risk tolerance threshold (step 4). At this point, the athlete is finally cleared for full RTS at the preillness training or competition level.

**RTS considerations following ARinf in the team setting**

As ARinf is a communicable disease, the physician must consider the risk not only from an individual but from a team perspective. A team environment, with locker rooms, meal sharing, shared equipment and accommodation is comparable to living in a family setting. In the family setting there are data that 20%–50% of susceptible members can become infected after exposure to viral ARinf such as rhinovirus, adenovirus and SARS-CoV-2. In general, viral transmission is most likely during the first 3–4 days of the infection, and isolation in the beginning of the symptomatic infection is recommended. Additional mitigation strategies, such as social distancing, and use of face masks and rigid hand hygiene can reduce the risk of viral transmission within teams. Knowledge of the specific virus, the viral shedding time and the transmission route helps to determine quarantine protocols, especially in the professional/elite sports environment and major competitions.

**EFFECTS OF ARINF ON EXERCISE AND SPORTS PERFORMANCE**

Improved understanding of the consequences of ARinf on an athlete's performance informs prevention, treatment, and medical care, and RTS. The potential effects of ARinf on exercise and sport performance can influence the progression from return-to-participation/training to full RTS. For this consensus, a systematic review by a subgroup of the IOC consensus group was commissioned to determine the effects of ARinf on exercise and sports performance in athletes.<sup>107</sup>

**Acute and longer-term effects of ARinf on exercise and sports performance**

Initial studies point towards a decrement in performance following an ARinf, with impairments to muscular, nervous system and cardiorespiratory capacities, reflecting muscle protein catabolism caused by illness. Impaired coordination ability and speed in

the performance of motor skills, reductions in submaximal force generation, slower reaction time, and decreased attention and vigilance, have been reported during allergic rhinoconjunctivitis<sup>108</sup> and respiratory infections.<sup>109</sup> However, some physiological attributes, including pulmonary function and  $\text{VO}_2\text{max}$ , seem to be robust in the presence of mild ARinf particularly when localised to the upper respiratory region. ARinf that causes moderate to severe symptoms is associated with a higher risk of negatively affecting performance compared with mild ARinf. Performance might also be influenced by the loss of training time due to the illness and this might constitute a major determinant of performance of athletes in elite competition.<sup>110</sup>

Studies show the acute effects of ARinf on sports performance parameters can reduce the likelihood to start a race if an athlete had a recent ARinf (8–12 days prior to a race),<sup>111</sup> compromise self-reported training ability and training capacity,<sup>112</sup> and impair running kinematics (measured stride length, stride frequency and joint angles).<sup>113</sup>

Reduced training load, training mileage and a reduction in sports performance points have been reported over several months following ARinf. Time lost to acute illness in training and competition success is a primary indicator of the effect of ARinf on sports performance. The likelihood of achieving success was increased by sevenfold in athletes able to complete >80% of planned training weeks.<sup>110</sup> Every week containing one or more days of modified training reduced the chances of achieving a key sports performance goal by 26%. Similarly, time-loss from training costs the recreational athlete highly anticipated participation in events, races, leagues, or competitions. Regardless of clinical significance, effects on performance including time lost due to acute illness, and an athlete's subjective (perceptual) experience of an acute illness, may be just as detrimental to sports performance outcomes as physical impairments.

**Other indirect effects of ARinf on exercise and sport**

The negative effects of ARinf on exercise and sports performance could be indirect in nature. For example, nasal congestion can disrupt sleep, impair coordination and visual coordination. Other indirect effects of ARinf include tiredness, fatigue, and impaired quality of life. Furthermore, adverse effects caused by commonly used medications (antihistamines or anticholinergic agents) might impair exercise performance. Physicians should consider a broad range of clinical effects, and together with the athlete and coach, consider other practical, sporting and lifestyle issues that could influence management of an ARinf, and the time course of RTS.

**PREVENTION OF ARINF IN ATHLETES**

Prevention of ARinf requires a multifaceted approach that minimises the risk of infection in an individual, the team and the people that they interact with, for example, team or technical support staff, media and spectators, within the environment which they are living in at that time. This is achieved through multiple measures including

**Table 8** A summary of risk factors associated with ARinf in athletes with prevention measures that can be considered

Risk category	Specific risk factor	Prevention measure
Individual athlete (internal risk factors)	Older age	▶ Age is a non-modifiable risk factor but be aware that older athletes and staff are more susceptible to ARinf
	Existing chronic respiratory conditions for example, allergies/asthma	▶ Screening for respiratory conditions (eg, at preseason, preparticipation, 'training camp' setting before competitions) ▶ Optimise treatment including medication ▶ Implement monitoring
	Existing other chronic diseases (eg, diabetes mellitus, obesity, hypertension, cardiovascular disease, chronic disease in other organ system)	▶ In general, these conditions are uncommon in younger athletes but if present they are associated with increased risk of ARinf or more severe ARinf ▶ Screening for chronic conditions (eg, at preseason, preparticipation, or at 'training camp' setting before competitions) ▶ Optimise treatment including medication ▶ Implement monitoring
	Health conditions that reduce immune function (immunocompromised athlete for example, organ transplant, athletes with negative energy balance)	▶ Increased awareness of risk ▶ Optimise other modifiable risk factors ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
	Para athlete	▶ Increased susceptibility to infection in sub-groups ▶ Be aware of increased risk of transmission through use of adaptive equipment, low vision, or intellectual impairment (eg, ability to social distance)
	Medications that negatively affect immune function (eg, systemic corticosteroids)	▶ Increased awareness of risk following systemic corticosteroid injections or oral corticosteroid use
	Confirmed recent exposure to athlete/staff/friend/family with ARinf	▶ Increased risk of ARinf ▶ Consider isolation ▶ Consider vitamin C and Zinc supplementation to reduce duration ▶ If pathogen is confirmed as influenza, consider anti-viral agents as prophylaxis
	Reduced sleep (quantity and quality) and recovery	▶ Adopt strategies that facilitate good quality sleep and correct sleep hygiene practices at night
	General nutrition	▶ Assess general nutritional status and implement personalised nutrition programmes ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
	Personal hygiene measures*	▶ Educate athletes on personal hygiene measures (maintain physical distance when in contact with potential infected individual, be aware of and avoid high touch surfaces, regular hand washing/hand sanitiser use, wearing of appropriate face masks)
Home environment	Increased risk to pathogen exposure in the social context	▶ Increased awareness of risk in household/family setting (especially young children) ▶ Consider isolation – as required
Sport type	Endurance sports	▶ Increased awareness of risk ▶ Consider periodic training load adjustments and increased monitoring ▶ Optimise other modifiable risk factors ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
	Winter sports	▶ Increased awareness of risk - greater monitoring ▶ Optimise other modifiable risk factors ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
Training/competition factors	Increased training load	▶ Increased awareness of risk ▶ Consider periodic training load adjustments and increased monitoring ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
	Inadequate recovery	▶ Diet, sleep education and monitoring, including personalised nutrition programmes
	Increased exposure to a wider sport team and support staff	▶ Reinforcing lifestyle and behavioural strategies. ▶ Develop team ethos to minimising infection
	Risk of transmission at the time of return-to-training and competition	▶ Consider transmission risk mitigation strategies as athletes return-to-training following an ARinf for example, avoiding in-person team meetings and team dining, using face masks, and making use of outdoor training venues ▶ Consider isolation of minimum of 3–4 days after symptom onset before return-to-training in a team setting
Season	Winter season	▶ Increased awareness of risk during winter seasons ▶ Consider training load adjustment and increased monitoring ▶ Optimise other modifiable risk factors ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
Vaccination	Influenza, SARS-CoV-2 vaccination, pneumococcus	▶ Encourage vaccination ▶ Adhere to local, regional, national and international health and vaccination regulations
International travel	Increased risk of pathogen exposure (on flight during travel, at the destination, using public transport)	▶ Encourage strict personal hygiene measures during long-haul and international travel ▶ Encourage appropriate mask wearing ▶ Be aware of higher risk seating positions on aircraft ▶ Encourage limitation of movement around the cabin during flight ▶ Consider probiotics, vitamin D, and vitamin C on an individual basis
Training and competition venues	Increased risk of pathogen exposure - team and support staff	▶ Increased awareness of risk transmission ▶ Consider higher risk environments such as accommodation, venue, dining, transport, media, exposure to the public ▶ Encourage personal hygiene measures and appropriate mask wearing
Epidemics/pandemics	Be aware of local and regional infectious disease patterns	▶ Conduct a full risk assessment of the risk status in a geographical area ▶ Plan and implement transmission risk mitigation strategies (eg, comply with full SARS-CoV-2 measures during the pandemic)
Poor ventilation	Poor ventilation in indoor sports venues	▶ Consider assessment and monitoring to ensure good ventilation at indoor sports venues

\*Personal hygiene measures can be applied widely as a transmission risk mitigation strategy.

general and specific education and health promotion, individualised risk assessment and introduction of specific strategies to reduce risk, minimise symptom duration and reduce risk of spread to others. Some of the measures will be specific to the environment the individual is operating in (eg, training, travel or competition), and others will be generic recommendations of vaccination,<sup>114</sup> hand hygiene,<sup>115 116</sup> cough etiquette, use of face masks,<sup>117</sup> promoting a

resilient immune system (eg, nutrition, recovery and sleep hygiene) and early reporting of symptoms.

The prevention of ARinf is related to the risk factors associated with ARinf. For this consensus a systematic review by a subgroup of the IOC consensus group was commissioned to review strategies for the prevention of ARinf in athletes. However, this review identified only a few articles that could be considered. A summary of the risk

categories with the specific risk factors, and the possible prevention measures for ARinf in athletes is summarised in [table 8](#). From this list, an SEM clinician can advise a spectrum of preventive measures based on several risk factors applicable and the prevailing situation combined the individual athlete's situation.

### SUMMARY AND FUTURE DIRECTIONS

The aim of this consensus was to provide the SEM clinician with an overview and practical clinical approach to ARinf in athletes. In summary, ARinfs in athletes are common, accounting for >50% of all illness-related consultations of an SEM clinician at major sports tournaments. Viral pathogens cause most ARinf, which present with several clinical syndromes, mostly as upper respiratory ARinf with or without systemic symptoms. Most ARinf in athletes (>80%) can be classified as mild, and do not have more than a short, transient and uncomplicated clinical course, which does not pose an increased risk for medical complications when exercise training continues or resumes. These asymptomatic or mild ARinf do not negatively affect exercise or sports performance. A small % of ARinf have a moderate to severe clinical presentation characterised by whole body and multiple symptoms, a more prolonged time course, and can be associated with regional respiratory complications or systemic multi-organ involvement. In these subgroups, there is an increased risk of medical complications as exercise training resumes after moderate to severe ARinf, which can also negatively affect exercise and sports performance. Although these complications and risks are rare, they need to be identified in athletes during the RTS process after ARinf. This process forms the basis of recommending a stepwise approach to RTS by risk stratifying athletes with ARinf, and then directing further more detailed assessment (clinical and by special investigations) to identify potential risk.

In this consensus, we suggest a practical stepwise clinical approach for this RTS process. Two novel and important contributions to this process are: (1) the recommendation that an exercise challenge test (self-administered or laboratory based) is performed before starting moderate- to high-intensity exercise training following an ARinf and (2) a recommendation for ongoing monitoring of symptoms and signs or abnormal training adaptation during the progressive RTS process. A further novel approach that we strongly advise is that athletes, coaches and medical staff be educated to (1) safely self-implement an exercise challenge test for asymptomatic or mild ARinf and (2) conduct ongoing self-monitoring during the RTS process, irrespective of the severity of ARinf.

Finally, we offer the following recommendations for future research and studies in this important field:

- ▶ Consider using a standardised approach in future epidemiological and clinical studies: (1) the suggested classification system of ARinf, (2) definitions of the clinical syndromes of ARinf and (3) the classification of severity of ARinf.
- ▶ Consider determining/documenting the specific pathogen responsible for ARinf in athletes. The use of scientific diagnostic methods to distinguish ARinf from ARill will enhance the quality of the current literature. This information will identify whether specific pathogens causing ARinf in athletes differ with respect to incidence, risk factors for ARinf, clinical presentation, pathology, illness severity, risk of multiple organ involvement, risk of medical complications during exercise, potential negative effects of pathogens on exercise and sport performance, and pathogen-specific RTS guidelines.
- ▶ Conducting studies to:
  - Validate and/or refine the proposed severity classification of ARinf in athletes.
  - Determine the effects of asymptomatic ARinf in athlete.
  - Quantify the effects of ARinf (pathogen specific) on exercise and sports performance.
  - Validate and/or refine the suggested RTS guidelines, including the efficacy of athlete/coach and support staff education.
  - Evaluate the efficacy of various prevention strategies and treatment options for ARinf in athletes.
  - Identify if there are any longer-term health and performance consequences of pathogen specific ARinf in athletes.

### Author affiliations

- <sup>1</sup>Sport, Exercise Medicine and Lifestyle Institute (SEMLI), Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
- <sup>2</sup>International Olympic Committee Research Centre, Pretoria, South Africa
- <sup>3</sup>Health and Science Department, World Athletics, Monaco, Monaco Principality
- <sup>4</sup>Laboratoire Motricité Humaine Expertise Sport Santé, Université Côte d'Azur, Nice, France
- <sup>5</sup>Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland
- <sup>6</sup>Department of Pediatric and Adolescent Medicine, Haukeland University Hospital, Bergen, Norway
- <sup>7</sup>Department of Clinical Science, University of Bergen, Bergen, Norway
- <sup>8</sup>Institute of Sport and Exercise Medicine (ISEM), Department of Sport Science, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
- <sup>9</sup>School of Human Science; Sports, Exercise and Health, University of Western Australia, Perth, Western Australia, Australia
- <sup>10</sup>Department of Respiratory Medicine, Royal Brompton Hospital, London, UK
- <sup>11</sup>Institute of Sport, Exercise and Health (ISEH), University College London (UCL), London, UK
- <sup>12</sup>Edge Day Hospital, Port Elizabeth, South Africa
- <sup>13</sup>Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany
- <sup>14</sup>Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark
- <sup>15</sup>Research Institute for Sport and Exercise, University of Canberra, Canberra, Australian Capital Territory, Australia
- <sup>16</sup>The Norwegian Olympic Sports Centre, Oslo, Norway
- <sup>17</sup>Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway
- <sup>18</sup>Institute for Sports Medicine, Alpine Medicine & Health Tourism (ISAG), University Hospital – Tirol Kliniken Innsbruck and Private University UMIT Tirol, Hall, Austria
- <sup>19</sup>Sports Medicine, Aspetar Orthopedic and Sports Medicine Hospital, Doha, Qatar
- <sup>20</sup>Research Center for Olympic Sports, Jyväskylä, Finland
- <sup>21</sup>Centre for Sport and Exercise Science and Medicine, University of Brighton, Brighton, UK

**Twitter** Paolo Emilio Adami @paolo\_emilio, Valerie Bougault @VBougault, Wayne Derman @wderman, Ken Fitch @NIL don't use twitter, Torbjørn Soligard @TSoligard and Nick Webborn @SportswiseUK

**Acknowledgements** The core members of the IOC consensus group and authors of this manuscript acknowledge the following subgroup corresponding members of the IOC consensus group on Acute Respiratory Illness in Athletes, who contributed to the generating and publishing review material that formed part of this consensus statement: Marelise Badenhorst, Maaïke Eken, Josu Gomez-Eceiza, Jane Fitzpatrick, Maree Gleeson, Lovemore Kunorozva, Katja Mjosund, Margo Mountjoy, Christopher Carlsen, Beat Villiger, Oliver Price, Vibeke Backer, Bruno Chenuel, Kjell Larsson, Carolette Snyders, Kelly Kaulback, Tod Olin, Thomas Halvorsen, Harald Hrubos-Strom.

**Contributors** All authors contributed to the initial draft and final version of the paper. All authors confirmed the final version to be published.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared except for the following: RB who works as Director for the IOC Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland. LE who works as Head of Scientific Activities for the IOC Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland. UE who is the Chair of the Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland. TS who works as Scientific Manager for the IOC Medical and Scientific Department, International Olympic Committee, Lausanne, Switzerland.

**Patient consent for publication** Not applicable.



**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

#### ORCID iDs

Martin Schwellnus <http://orcid.org/0000-0003-3647-0429>  
 Paolo Emilio Adami <http://orcid.org/0000-0001-5975-5342>  
 Valerie Bougault <http://orcid.org/0000-0002-2258-6562>  
 Wayne Derman <http://orcid.org/0000-0002-8879-177X>  
 Ken Fitch <http://orcid.org/0000-0003-1303-0535>  
 James H Hull <http://orcid.org/0000-0003-4697-1526>  
 Tim Meyer <http://orcid.org/0000-0003-3425-4546>  
 Lars Pedersen <http://orcid.org/0000-0002-5950-652X>  
 Wolfgang Schobersberger <http://orcid.org/0000-0002-5657-0307>  
 Yorck Olaf Schumacher <http://orcid.org/0000-0003-0381-618X>  
 Nicola Sewry <http://orcid.org/0000-0003-1022-4780>  
 Torbjørn Soligard <http://orcid.org/0000-0001-8863-4574>  
 Maarit Valtonen <http://orcid.org/0000-0001-8883-2255>  
 Nick Webborn <http://orcid.org/0000-0003-3636-5557>

#### REFERENCES

- Rogge J. An ounce of prevention? *Br J Sports Med* 2009;43:627.
- Alonso J-M, Edouard P, Fischetto G, et al. Determination of future prevention strategies in elite track and field: analysis of Daegu 2011 IAAF Championships injuries and illnesses surveillance. *Br J Sports Med* 2012;46:505–14.
- Alonso J-M, Tscholl PM, Engebretsen L, et al. Occurrence of injuries and illnesses during the 2009 IAAF world athletics Championships. *Br J Sports Med* 2010;44:1100–5.
- Dvorak J, Junge A, Derman W, et al. Injuries and illnesses of football players during the 2010 FIFA World cup. *Br J Sports Med* 2011;45:626–30.
- Edouard P, Depieppe F, Hertert P, et al. Injuries and illnesses during the 2011 Paris European athletics indoor Championships. *Scand J Med Sci Sports* 2013;23:e213–8.
- Edouard P, Junge A, Sorg M, et al. Illnesses during 11 international athletics championships between 2009 and 2017: incidence, characteristics and sex-specific and discipline-specific differences. *Br J Sports Med* 2019;53:1174–82.
- Mountjoy M, Junge A, Alonso JM, et al. Sports injuries and illnesses in the 2009 FINA world Championships (Aquatics). *Br J Sports Med* 2010;44:522–7.
- Schwellnus M, Derman W, Page T, et al. Illness during the 2010 super 14 rugby Union tournament – a prospective study involving 22 676 player days. *Br J Sports Med* 2012;46:499–504.
- Theron N, Schwellnus M, Derman W, et al. Illness and injuries in elite football players—a prospective cohort study during the FIFA Confederations cup 2009. *Clinical Journal of Sport Medicine* 2013;23:379–83.
- Engebretsen L, Soligard T, Steffen K, et al. Sports injuries and illnesses during the London summer Olympic Games 2012. *Br J Sports Med* 2013;47:407–14.
- Engebretsen L, Steffen K, Alonso JM, et al. Sports injuries and illnesses during the winter Olympic Games 2010. *Br J Sports Med* 2010;44:772–80.
- Soligard T, Steffen K, Palmer D, et al. Sports injury and illness incidence in the Rio de Janeiro 2016 Olympic summer games: a prospective study of 11274 athletes from 207 countries. *Br J Sports Med* 2017;51:1265–71.
- Soligard T, Steffen K, Palmer-Green D, et al. Sports injuries and illnesses in the Sochi 2014 Olympic winter games. *Br J Sports Med* 2015;49:441–7.
- Soligard T, Palmer D, Steffen K, et al. Sports injury and illness incidence in the PyeongChang 2018 Olympic winter games: a prospective study of 2914 athletes from 92 countries. *Br J Sports Med* 2019;53:1085–92.
- Derman W, Schwellnus MP, Jordaan E, et al. Sport, sex and age increase risk of illness at the Rio 2016 summer Paralympic games: a prospective cohort study of 51 198 athlete days. *Br J Sports Med* 2018;52:17–23.
- Derman W, Schwellnus MP, Jordaan E, et al. The incidence and patterns of illness at the Sochi 2014 winter Paralympic games: a prospective cohort study of 6564 athlete days. *Br J Sports Med* 2016;50:1064–8.
- Gawroński W, Sobiecka J, Malesza J. Fit and healthy Paralympians—medical care guidelines for disabled athletes: a study of the injuries and illnesses incurred by the Polish Paralympic team in Beijing 2008 and London 2012. *Br J Sports Med* 2013;47:844–9.
- Steffen K, Moseid CH, Engebretsen L, et al. Sports injuries and illnesses in the Lillehammer 2016 youth Olympic winter games. *Br J Sports Med* 2017;51:29–35.
- Steffen K, Soligard T, Mountjoy M, et al. How do the new Olympic sports compare with the traditional Olympic sports? injury and illness at the 2018 youth Olympic summer games in Buenos Aires, Argentina. *Br J Sports Med* 2020;54:168–75.
- Derman W, Runciman P, Jordaan E. Incidence rate and burden of illness at the Pyeongchang 2018 Paralympic winter games. *Br J Sports Med* 2019;bjssports-2018-100096.
- Derman W, Schwellnus M, Jordaan E. Clinical characteristics of 385 illnesses of athletes with impairment reported on the WEB-IISS system during the London 2012 Paralympic Games. *PM&R* 2014;6:S23–30.
- Derman EW, Badenhorst M, Eken M. Incidence of acute respiratory illnesses in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus on “acute respiratory illness in the athlete”. *Br J Sports Med* 2022.
- Schwellnus M, Adami PE, Bougault V. International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes Part 2: non-infective acute respiratory illness. *Br J Sports Med* 2022. online.
- Schwellnus M, Adami PE, Bougault V. International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes Part 3: SARS-CoV-2 infection in athletes. *Br J Sports Med* 2022. In Review.
- Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. *Rhinology* 2020;58:1–464.
- Hens G, Hellings PW. The nose: gatekeeper and trigger of bronchial disease. *Rhinology* 2006;44:179–87.
- Snyders C, Pyne DB, Sevry N. Acute respiratory illness and return to sport: a systematic review and meta-analysis by a subgroup of the IOC consensus on ‘acute respiratory illness in the athlete’. *Br J Sports Med* 2021.
- Barrett B, Locken K, Maberry R. The Wisconsin upper respiratory symptom survey (WURSS): a new research instrument for assessing the common cold. *J Family Practice* 2002;51:265.
- Jackson GG, Dowling HF. Transmission of the common cold to volunteers under controlled conditions. IV. specific immunity to the common cold. *J Clin Invest* 1959;38:762–9.
- Matthews A, Pyne D, Saunders P, et al. A self-reported questionnaire for quantifying illness symptoms in elite athletes. *Open Access J Sports Med* 2010;1:15–22.
- Fricker PA, Pyne DB, Saunders PU, et al. Influence of training loads on patterns of illness in elite distance runners. *Clinical Journal of Sport Medicine* 2005;15:246–52.
- Mäkelä MJ, Puhakka T, Ruuskanen O, et al. Viruses and bacteria in the etiology of the common cold. *J Clin Microbiol* 1998;36:539–42.
- Ruuskanen O, Waris M, Ramilo O. New aspects on human rhinovirus infections. *Pediatr Infect Dis J* 2013;32:553–5.
- Treanor J. *Respiratory infections*. Washington DC: ASM Press, 2017.
- Tang J, Chen J, He T, et al. Diversity of upper respiratory tract infections and prevalence of Streptococcus pneumoniae colonization among patients with fever and flu-like symptoms. *BMC Infect Dis* 2019;19:24.
- Cox AJ, Gleeson M, Pyne DB, et al. Clinical and laboratory evaluation of upper respiratory symptoms in elite athletes. *Clin J Sport Med* 2008;18:438–45.
- Gundlapalli AV, Rubin MA, Samore MH, et al. Influenza, winter olympiad, 2002. *Emerg Infect Dis* 2006;12:144–6.
- Spence L, Brown WJ, Pyne DB, et al. Incidence, etiology, and symptomatology of upper respiratory illness in elite athletes. *Med Sci Sports Exerc* 2007;39:577–86.
- Valtonen M, Grönroos W, Luoto R, et al. Increased risk of respiratory viral infections in elite athletes: a controlled study. *PLoS One* 2021;16:e0250907.
- Valtonen M, Waris M, Vuorinen T, et al. Common cold in team Finland during 2018 winter Olympic Games (PyeongChang): epidemiology, diagnosis including molecular point-of-care testing (POCT) and treatment. *Br J Sports Med* 2019;53:1093–8.
- Ruuskanen O, Luoto R, Valtonen M, et al. Respiratory viral infections in athletes: many unanswered questions. *Sports Medicine*. In Press 2022;31.
- Brendish NJ, Malachira AK, Armstrong L, et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. *The Lancet Respiratory Medicine* 2017;5:401–11.
- Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's diagnostics Committee. *Clin Infect Dis* 2020;71:2744–51.
- Aoki A, Ashizawa T, Ebata A, et al. Group A Streptococcus pharyngitis outbreak among university students in a judo Club. *Journal of Infection and Chemotherapy* 2014;20:190–3.
- Jones B, Phillips G, Kemp S, et al. SARS-CoV-2 transmission during rugby League matches: do players become infected after participating with SARS-CoV-2 positive players? *Br J Sports Med* 2021;55:807–13.
- Meyer T, Mack D, Donde K, et al. Successful return to professional men's football (soccer) competition after the COVID-19 shutdown: a cohort study in the German Bundesliga. *Br J Sports Med* 2021;55:62–6.
- Pedersen L, Lindberg J, Lind RR, et al. Reopening elite sport during the COVID-19 pandemic: experiences from a controlled return to elite football in Denmark. *Scand J Med Sci Sports* 2021;31:936–9.
- Schumacher YO, Tabben M, Hassoun K. Resuming professional football (soccer) during the COVID-19 pandemic in a country with high infection rates: a prospective cohort study. *Br J Sports Med* 2021;bjssports-2020-103724.

- 49 Watson AM, Haraldsdottir K, Biese K, *et al.* The association of COVID-19 incidence with sport and face mask use in United States high school athletes. *J Athl Train* 2021. doi:10.4085/1062-6050-281-21. [Epub ahead of print: 18 Nov 2021].
- 50 Gao CX, Li Y, Wei J, *et al.* Multi-route respiratory infection: when a transmission route may dominate. *Sci Total Environ* 2021;752:141856.
- 51 Dasaraju PV, Liu C. Infections of the respiratory system. In: *Medical microbiology*. 4th edn, 1996.
- 52 Kuchar E, Miśkiewicz K, Nitsch-Osusch A. Pathophysiology of clinical symptoms in acute viral respiratory tract infections. In: Pokorski M, ed. *Pulmonary infection*. Cham: Springer International Publishing, 2015: 25–38.
- 53 Kutter JS, Spronken MI, Fraaij PL, *et al.* Transmission routes of respiratory viruses among humans. *Curr Opin Virol* 2018;28:142–51.
- 54 Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. *Open Forum Infect Dis* 2015;2.
- 55 Arruda E, Pitkäranta A, Witek TJ, *et al.* Frequency and natural history of rhinovirus infections in adults during autumn. *J Clin Microbiol* 1997;35:2864–8.
- 56 Lynch JP, Fishbein M, Echavarría M, eds. *Adenovirus. Sem Respir Crit Care Med*. © Thieme Medical Publishers, 2011.
- 57 Yan D, Zhang X, Chen C, *et al.* Characteristics of viral shedding time in SARS-CoV-2 infections: a systematic review and meta-analysis. *Front Public Health* 2021;9:652842.
- 58 Brito D, Meester S, Yanamala N, *et al.* High prevalence of pericardial involvement in college student athletes recovering from COVID-19. *JACC: Cardiovascular Imaging* 2021;14:541–55.
- 59 Rajpal S, Tong MS, Borchers J, *et al.* Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. *JAMA Cardiol* 2021;6:116–8.
- 60 Daniels CJ, Rajpal S, Greenshields JT, *et al.* Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. *JAMA Cardiol* 2021;6:1078–87.
- 61 Moulson N, Petek BJ, Drezner JA, *et al.* SARS-CoV-2 cardiac involvement in young competitive athletes. *Circulation* 2021;144:256–66.
- 62 Udelson JE, Rowin EJ, Maron BJ. Return to play for athletes after COVID-19 infection: the fog begins to clear. *JAMA Cardiol* 2021;6:997–9.
- 63 Derman EW, Badenhorst M, Eken M. Risk factors associated with acute respiratory illnesses in athletes: A systematic review by a subgroup of the IOC consensus on "Acute respiratory illness in the athlete". *Br J Sports Med* 2022.
- 64 Eccles R. Understanding the symptoms of the common cold and influenza. *Lancet Infect Dis* 2005;5:718–25.
- 65 Carrat F, Vergu E, Ferguson NM, *et al.* Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am J Epidemiol* 2008;167:775–85.
- 66 Jain S, Gautam V, Naseem S. Acute-Phase proteins: as diagnostic tool. *J Pharm Bioallied Sci* 2011;3:118–27.
- 67 Huang H-S, Tsai C-L, Chang J, *et al.* Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. *Clinical Microbiology and Infection* 2018;24:1055–63.
- 68 Mackay IM. Real-Time PCR in the microbiology laboratory. *Clinical Microbiology and Infection* 2004;10:190–212.
- 69 Smith RL, Gibson LL, Martinez PP. Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection. *medRxiv* 2021.
- 70 Chartrand C, Tremblay N, Renaud C, *et al.* Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. *J Clin Microbiol* 2015;53:3738–49.
- 71 Gunell M, Antikainen P, Porjo N, *et al.* Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and 2014 obtained from an automated and multianalyte marioPCC® respiratory pathogen test. *Eur J Clin Microbiol Infect Dis* 2016;35:405–13.
- 72 Jartti T, Söderlund-Venermo M, Hedman K, *et al.* New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. *Paediatr Respir Rev* 2013;14:38–45.
- 73 Li H, McCormac MA, Estes RW, *et al.* Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. *J Clin Microbiol* 2007;45:2105–9.
- 74 Somerville LK, Mala Ratnamohan V, Dwyer DE, *et al.* Molecular diagnosis of respiratory viruses. *Pathology* 2015;47:243–9.
- 75 Babady NE. The FilmArray® respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. *Expert Rev Mol Diagn* 2013;13:779–88.
- 76 Hanada S, Pirzadeh M, Carver KY, *et al.* Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. *Front Immunol* 2018;9.
- 77 Feikin DR, Fu W, Park DE, *et al.* Is higher viral load in the upper respiratory tract associated with severe pneumonia? findings from the PERCH study. *Clin Infect Dis* 2017;64:S337–46.
- 78 Nabhan D, Windt J, Taylor D, *et al.* Close encounters of the US kind: illness and injury among US athletes at the PyeongChang 2018 winter Olympic Games. *Br J Sports Med* 2020;54:997–1002.
- 79 Li X, Zhong X, Wang Y, *et al.* Clinical determinants of the severity of COVID-19: a systematic review and meta-analysis. *PLoS One* 2021;16:e0250602.
- 80 Walsh NP. Nutrition and athlete immune health: new perspectives on an old paradigm. *Sports Med* 2019;49:153–68.
- 81 Palmowski J, Boßlau T, Ryl L. Managing immune health in sports—A practical guide for athletes and coaches [Infektprävention im Leistungssport—Ein praktischer Leitfaden für Trainer und Sportler]. *Deutsche Zeitschrift für Sportmedizin* 70 2019;70:219–26.
- 82 Williams NC, Killer SC, Svendsen IS, *et al.* Immune nutrition and exercise: narrative review and practical recommendations. *Eur J Sport Sci* 2019;19:49–61.
- 83 Hojyo S, Fukada T. Roles of zinc signaling in the immune system. *J Immunol Res* 2016;2016:1–21.
- 84 Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. *Nutrients* 2017;9:1286.
- 85 Roth M, Fang L, Stolz D, *et al.* Pelargonium sidoides Radix extract Eps 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. *PLoS One* 2019;14:e0210702.
- 86 Timmer A, Günther J, Motschall E, *et al.* Pelargonium sidoides extract for treating acute respiratory tract infections. *Cochrane Database Syst Rev* 2013;47:CD006323.
- 87 Karsch-Völk M, Barrett B, Linde K. *Echinacea* for Preventing and Treating the Common Cold. *JAMA* 2015;313:618–9.
- 88 Pyne DB, West NP, Cox AJ, *et al.* Probiotics supplementation for athletes – clinical and physiological effects. *Eur J Sport Sci* 2015;15:63–72.
- 89 Lee N, Hui DSC, Zuo Z, *et al.* A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. *Clinical Infectious Diseases* 2013;57:1511–9.
- 90 Paules C, Subbarao K. Influenza. *The Lancet* 2017;390:697–708.
- 91 Heikkinen T, Järvinen A. The common cold. *The Lancet* 2003;361:51–9.
- 92 Ardern CL, Glasgow P, Schneiders A, *et al.* 2016 consensus statement on return to sport from the first world Congress in sports physical therapy, Bern. *Br J Sports Med* 2016;50:853–64.
- 93 Shrier I. Strategic assessment of risk and risk tolerance (StARRT) framework for return-to-play decision-making. *Br J Sports Med* 2015;49:1311–5.
- 94 Eichner ER. Infection, immunity, and exercise. *Phys Sportsmed* 1993;21:125–35.
- 95 Primos WA. Sports and exercise during acute illness. *Phys Sportsmed* 1996;24:44–54.
- 96 Metz JP. Upper respiratory tract infections. *Curr Sports Med Rep* 2003;2:84–90.
- 97 Scharhag J, Meyer T. Return to play after acute infectious disease in football players. *J Sports Sci* 2014;32:1237–42.
- 98 Diamond AB, Narducci DM, Roberts WO, *et al.* Interim guidance on the preparticipation physical examination for athletes during the SARS-CoV-2 pandemic. *Clinical Journal of Sport Medicine* 2021;31:1–6.
- 99 Kim JH, Levine BD, Phelan D, *et al.* Coronavirus disease 2019 and the athletic heart: emerging perspectives on pathology, risks, and return to play. *JAMA Cardiol* 2021;6:219–27.
- 100 Löllgen H, Bachl N, Papadopoulou T, *et al.* Recommendations for return to sport during the SARS-CoV-2 pandemic. *BMJ Open Sport Exerc Med* 2020;6:e000858.
- 101 Metz J, McElheny K, Robinson JN, *et al.* Considerations for return to exercise following mild-to-moderate COVID-19 in the recreational athlete. *Hss J* 2020;16:102–7.
- 102 Ross R, Irvin L, Severin R, *et al.* Return-to-Play considerations after COVID-19 infection in elite athletes. *J Athl Train* 2021;56:1061–3.
- 103 Wilson MG, Hull JH, Rogers J, *et al.* Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians. *Br J Sports Med* 2020;54:1157–61.
- 104 Cavigli L, Cillis M, Mochi V, *et al.* SARS-CoV-2 infection and return to play in junior competitive athletes: is systematic cardiac screening needed? *Br J Sports Med* 2022;56:264–70.
- 105 Cavigli L, Frascaro F, Turchini F, *et al.* A prospective study on the consequences of SARS-CoV-2 infection on the heart of young adult competitive athletes: implications for a safe return-to-play. *Int J Cardiol* 2021;336:130–6.
- 106 Petek BJ, Moulson N, Baggish AL, *et al.* Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the outcomes Registry for cardiac conditions in athletes (ORCCA). *Br J Sports Med* 2021;27:bjssports-2021-104644.
- 107 Kaulback K, Pyne DB, Hull JH, *et al.* The effects of acute respiratory illness on exercise and sports performance outcomes in athletes - a systematic review by a subgroup of the IOC consensus group on "Acute respiratory illness in the athlete". *Eur J Sport Sci* 2022:1–57.
- 108 Derman EW, Hawarden D, Schwelnus MP. Allergic rhinoconjunctivitis in athletes - mechanisms of impaired performance and implications for management. *Curr Allerg Clin Immunol* 2010;23:59–62.
- 109 Friman G, Wesslén L. Infections and exercise in high-performance athletes. *Immunol Cell Biol* 2000;78:510–22.
- 110 Raysmith BP, Drew MK. Performance success or failure is influenced by weeks lost to injury and illness in elite Australian track and field athletes: a 5-year prospective study. *J Sci Med Sport* 2016;19:778–83.

- 111 Van Tonder A, Schwellnus M, Swanevelder S, *et al.* A prospective cohort study of 7031 distance runners shows that 1 in 13 report systemic symptoms of an acute illness in the 8-12 day period before a race, increasing their risk of not finishing the race 1.9 times for those runners who started the race: SAFER study IV. *Br J Sports Med* 2016;50:939-45.
- 112 Michalickova D, Minic R, Dikic N, *et al.* *Lactobacillus helveticus* Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. *Appl Physiol Nutr Metab* 2016;41:782-9.
- 113 Weidner TG, Gehlsen G, Dwyer GB, *et al.* Effects of viral upper respiratory illness on running gait. *J Athl Train* 1997;32:309-14.
- 114 Gärtner BC, Meyer T. Vaccination in elite athletes. *Sports Medicine* 2014;44:1361-76.
- 115 Aiello AE, Coulborn RM, Perez V, *et al.* Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. *Am J Public Health* 2008;98:1372-81.
- 116 Warren-Gash C, Fragaszy E, Hayward AC. Hand hygiene to reduce community transmission of influenza and acute respiratory tract infection: a systematic review. *Influenza Other Respi Viruses* 2013;7:738-49.
- 117 Brainard J, Jones NR, Lake IR, *et al.* Community use of face masks and similar barriers to prevent respiratory illness such as COVID-19: a rapid scoping review. *Euro Surveill* 2020;25:2000725.
- 118 Guibas GV, Papadopoulos NG. Viral upper respiratory tract infections. In: Green RJ, ed. *Viral infections in children*. Volume II. Cham: Springer International Publishing, 2017: 1-25.
- 119 Bellei N, Carraro E, Perosa A, *et al.* Acute respiratory infection and influenza-like illness viral etiologies in Brazilian adults. *J Med Virol* 2008;80:1824-7.
- 120 Falsey AR, McElhanev JE, Beran J, *et al.* Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. *J Infect Dis* 2014;209:1873-81.
- 121 Howard PF, McCaw JM, Richmond PC, *et al.* Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial. *Influenza Other Respi Viruses* 2013;7:330-9.
- 122 Kelly H, Birch C. The causes and diagnosis of influenza-like illness. *Aust Fam Physician* 2004;33:305-9.
- 123 Mullins J, Cook R, Rinaldo C, *et al.* Influenza-Like illness among university students: symptom severity and duration due to influenza virus infection compared to other etiologies. *J. of Am. Coll. Hlth.* 2011;59:246-51.
- 124 Renois F, Talmud D, Huguenin A, *et al.* Rapid detection of respiratory tract viral infections and coinfections in patients with influenza-like illnesses by use of reverse transcription-PCR DNA microarray systems. *J Clin Microbiol* 2010;48:3836-42.
- 125 Santamaría C, Uruña A, Videla C, *et al.* Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina. *Influenza Other Respi Viruses* 2008;2:131-4.
- 126 Schnepf N, Resche-Rigon M, Chaillon A, *et al.* High burden of non-influenza viruses in influenza-like illness in the early weeks of H1N1v epidemic in France. *PLoS One* 2011;6:e23514.
- 127 Wenzel RP, Fowler AA. Acute bronchitis. *New England Journal of Medicine* 2006;355:2125-30.
- 128 Smoot MK, Hosey RG. Pulmonary infections in the athlete. *Curr Sports Med Rep* 2009;8:71-5.
- 129 Grande AJ, Keogh J, Silva V, *et al.* Exercise versus no exercise for the occurrence, severity, and duration of acute respiratory infections. *Cochrane Database Syst Rev* 2020;2020.
- 130 Guppy MPB, Mickan SM, Del Mar CB, *et al.* Advising patients to increase fluid intake for treating acute respiratory infections. *Cochrane Database of Systematic Reviews* 2011;12.
- 131 King D, Mitchell B, Williams CP, *et al.* Saline nasal irrigation for acute upper respiratory tract infections. *Cochrane Database of Systematic Reviews* 2015;7.
- 132 Singh M, Singh M, Jaiswal N, *et al.* Heated, humidified air for the common cold. *Cochrane Database Syst Rev* 2017;8:CD001728.
- 133 Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. *Cochrane Database Syst Rev* 2013:CD000980.
- 134 Balla M, Merugu GP, Konala VM, *et al.* Back to basics: review on vitamin D and respiratory viral infections including COVID-19. *J Community Hosp Intern Med Perspect* 2020;10:529-36.
- 135 Hunter J, Arentz S, Goldenberg J, *et al.* Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 2021;11:e047474.
- 136 Wu T, Zhang J, Qiu Y, *et al.* Chinese medicinal herbs for the common cold. *Cochrane Database Syst Rev* 2007;17:CD004782.
- 137 Hao Q, Dong BR, Wu T, *et al.* Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database Syst Rev* 2015;5.
- 138 Chalumeau M, Duijvestijn YCM, Cochrane Acute Respiratory Infections Group. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. *Cochrane Database Syst Rev* 2013;54.
- 139 Venekamp RP, Thompson MJ, Hayward G, *et al.* Systemic corticosteroids for acute sinusitis. *Cochrane Database Syst Rev* 2014;107.
- 140 Hayward G, Thompson MJ, Perera R, *et al.* Corticosteroids as standalone or add-on treatment for sore throat. *Cochrane Database of Systematic Reviews* 2012;41:CD008268.
- 141 Sadeghirad B, Siemieniuk RAC, Brignardello-Petersen R, *et al.* Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials. *BMJ* 2017;358:j3887.
- 142 Deckx L, De Sutter AI, Guo L, *et al.* Nasal decongestants in monotherapy for the common cold. *Cochrane Database Syst Rev* 2016;10:CD009612.
- 143 Smith SM, Schroeder K, Fahey T. Over-The-Counter (OTC) medications for acute cough in children and adults in community settings. *Cochrane Database Syst Rev* 2014;10:CD001831.
- 144 De Sutter AIM, Saraswat A, van Driel ML, *et al.* Antihistamines for the common cold. *Cochrane Database of Systematic Reviews* 2015;67.
- 145 De Sutter AI, Eriksson L, van Driel ML. Oral antihistamine-decongestant-analgesic combinations for the common cold. *Cochrane Database Syst Rev* 2022;1:CD004976.
- 146 De Sutter AIM, van Driel ML, Kumar AA, *et al.* Oral antihistamine-decongestant-analgesic combinations for the common cold. *Cochrane Database Syst Rev* 2012;77.
- 147 AlBalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. *Cochrane Database Syst Rev* 2013;123:CD008231.
- 148 Jefferson T, Jones MA, Doshi P, *et al.* Neuraminidase inhibitors for preventing and treating influenza in adults and children. *Cochrane Database Syst Rev* 2014;19.
- 149 Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. *Cochrane Database Syst Rev* 2013;51:CD000247.
- 150 Lemiengre MB, van Driel ML, Merenstein D, *et al.* Antibiotics for acute rhinosinusitis in adults. *Cochrane Database Syst Rev* 2018;2018.
- 151 Spinks A, Glasziou PP, Del Mar CB. Antibiotics for treatment of sore throat in children and adults. *Cochrane Database Syst Rev* 2021;12:CD000023.
- 152 Reveiz L, Cardona AF. Antibiotics for acute Laryngitis in adults. *Cochrane Database Syst Rev* 2015;94:CD004783.

**Supplementary Table S1: Potential regional and systemic complications in other organs / organ systems that are associated with viral pathogens causing acute respiratory infection (ARinf)**

Specific organ / organ system	Potential complications	Examples of viral pathogens associated with complications
<b>Respiratory tract</b> (regional complications)	Otitis media (1-5)	Influenza B, Rhinovirus, Respiratory Syncytial Virus (RSV), Parainfluenza
	Sinusitis (2, 6)	Rhinovirus, Parainfluenza
	Pharyngitis (2, 3, 5-9)	Influenza A, Influenza B, Rhinovirus, Coronavirus, Enterovirus, Parainfluenza, SARS-CoV-2
	Tonsillitis (9)	Adenovirus
	Pneumonia (2, 6, 10-12)	SARS-CoV-2, Influenza type A and B, Respiratory syncytial virus (RSV), Human Metapneumovirus, Enterovirus, Parainfluenza type 3
	Bronchitis / bronchiolitis (5, 6, 10, 12-16)	SARS-CoV-2, Respiratory syncytial virus (RSV), Human Metapneumovirus, Rhinovirus, Adenovirus, Enterovirus,
	Post-infective bronchial hyperreactivity, asthma exacerbations (1, 17)	Rhinoviruses, Adenovirus
<b>Cardiovascular</b>	Myocarditis (2, 6, 18-22)	SARS-CoV-2, Enterovirus, Parainfluenza, Influenza virus A and B, Adenovirus
	Pericarditis (2, 6, 21-25)	SARS-CoV-2, Rhinovirus, Enterovirus, Parainfluenza
<b>Nervous system</b>	Encephalitis (6, 13, 26)	Adenovirus, Enterovirus
	Meningitis (2, 6, 13)	Enterovirus, Parainfluenza
	Autonomic dysfunction (POTS and IST) (24, 27-29)	SARS-CoV-2
	Cognitive dysfunction (30-33)	SARS-CoV-2
	Post-viral fatigue syndrome (33-36)	Epstein Barr virus, SARS-CoV-2
<b>Renal / bladder</b>	Nephritis (37); Nephrotic Disease (2, 26)	Adenovirus, Parainfluenza, SARS-CoV-2
	Cystitis (26)	Adenovirus
<b>Gastrointestinal</b>	Gastroenteritis (6, 13, 38-40)	Coronavirus, Influenza A, Influenza B, Rhinovirus, Chlamydia pneumoniae, SARS-CoV-2
	Hepatitis (13, 22, 26); Hepatic injury(41)	Adenovirus, Enterovirus, Mycoplasma pneumoniae, SARS-CoV-2
<b>Musculoskeletal</b>	Myositis (42, 43); Rhabdomyolysis (2)	Parainfluenza virus, SARS-CoV-2
	Arthritis (44)	SARS-CoV-2
<b>Psychiatric</b>	Post infective psychiatric disorders e.g. anxiety, depression, insomnia and other sleep disorders) (30, 45, 46)	SARS-CoV-2

POTS: Postural orthostatic tachycardia syndrome; IST: Inappropriate Sinus Tachycardia



**Supplementary Table S2: Symptoms of acute respiratory infections (ARinf) (by predominant anatomical regions)**

Predominant anatomical region	Symptom
Upper respiratory tract	Blocked/plugged nose <sup>a</sup>
	Runny nose <sup>a</sup>
	Sneezing <sup>a</sup>
	Altered/loss sense of smell <sup>b</sup>
	Altered/loss sense of taste <sup>b</sup>
	Sinus pressure <sup>a</sup>
	Sore/scratchy throat <sup>b</sup>
Hoarseness <sup>a</sup>	
Lower respiratory tract and regional (head / neck region)	Dry cough <sup>a*</sup>
	Wet cough (productive) <sup>b</sup>
	Difficulty in breathing <sup>a</sup>
	Fast breathing or shortness of breath <sup>a</sup>
	Chest pain/pressure <sup>b</sup>
	Chest tightness <sup>a</sup>
	Headache <sup>b</sup>
Red / watery / scratchy eyes <sup>a</sup>	
Systemic / whole body / non-respiratory	Fever <sup>b</sup>
	Chills <sup>b</sup>
	Excessive fatigue <sup>b</sup>
	General muscle aches and pains <sup>b</sup>
	Skin rash <sup>a</sup>
	Abdominal pain <sup>b</sup>
	Nausea <sup>b</sup>
	Vomiting <sup>b</sup>
Diarrhoea <sup>b</sup>	
Loss of appetite <sup>b</sup>	

<sup>a</sup>: Symptoms that can be associated with both non-infective acute respiratory illness (ARill) and ARinf:

<sup>b</sup>: Symptoms that are more indicative of an ARinf

\*: Cough can also be an upper respiratory tract symptom (originate above the larynx)

**Supplementary Table S3: Viral pathogens causing clinical syndromes of acute respiratory infection (ARinf) in adults (adapted from Traenor J, 2016, Clinical Virology)(47)**

Main anatomical classification	Clinical syndromes of ARinf in athletes	Viral pathogens causing clinical syndromes (adults)			Refs
		Common (>25% cases)	Fairly common (5-25% cases)	Rare (<5% cases)	
Predominantly upper respiratory tract	1. Acute rhinitis and / or additional features of rhinosinusitis / rhinopharyngitis *: “Common cold”, “Coryza”, “viral upper respiratory infection”	<ul style="list-style-type: none"> <li>• Rhinovirus</li> </ul>	<ul style="list-style-type: none"> <li>• Enterovirus</li> <li>• Coronavirus</li> <li>• Respiratory syncytial virus</li> </ul>	<ul style="list-style-type: none"> <li>• Influenza Type A (children)</li> <li>• Influenza Type B</li> <li>• Parainfluenza Type 1</li> <li>• Parainfluenza Type 2</li> <li>• Parainfluenza Type 3</li> </ul>	(47, 48)
	2. Acute rhinosinusitis / rhinopharyngitis with systemic symptoms / signs **: “Influenza-like”, “flu-like”, “flu”	<ul style="list-style-type: none"> <li>• Influenza Type A</li> <li>• Rhinovirus (children)</li> </ul>	<ul style="list-style-type: none"> <li>• Parainfluenza viruses (children)</li> </ul>	<ul style="list-style-type: none"> <li>• Influenza Type B</li> <li>• Adenovirus</li> <li>• Respiratory syncytial virus</li> <li>• Human metapneumovirus</li> <li>• Coronavirus</li> <li>• Bocavirus</li> </ul>	(49-54)
	3. Acute pharyngitis / tonsillitis (with or without systemic symptoms / signs)		<ul style="list-style-type: none"> <li>• Influenza Type A</li> <li>• Influenza Type B</li> <li>• Parainfluenza Type 1</li> <li>• Parainfluenza Type 2</li> <li>• Parainfluenza Type 3</li> <li>• Rhinovirus</li> <li>• Enterovirus</li> <li>• Adenovirus</li> <li>• Epstein-Barr virus</li> </ul>	<ul style="list-style-type: none"> <li>• Respiratory syncytial virus</li> <li>• Coronavirus</li> <li>• Herpes simplex virus</li> <li>• Cytomegalovirus</li> </ul>	(47, 48)
	4. Acute laryngitis / laryngotracheobronchitis (with or without systemic symptoms / signs) ***: “Croup”	<ul style="list-style-type: none"> <li>• Parainfluenza Type 1</li> </ul>	<ul style="list-style-type: none"> <li>• Influenza Type A</li> <li>• Parainfluenza Type 2</li> <li>• Parainfluenza Type 3</li> <li>• Respiratory syncytial virus</li> <li>• Coronavirus</li> <li>• Adenovirus</li> </ul>		(47, 48)
Predominantly lower respiratory tract	5. Acute tracheobronchitis with or without systemic symptoms / signs)		<ul style="list-style-type: none"> <li>• Influenza Type A</li> <li>• Influenza Type B</li> </ul>	<ul style="list-style-type: none"> <li>• Parainfluenza Type 1</li> <li>• Parainfluenza Type 2</li> <li>• Parainfluenza Type 3</li> <li>• Measles virus</li> <li>• Adenovirus</li> <li>• Herpes simplex virus</li> </ul>	(47, 48)
	6. Acute bronchitis / bronchiolitis with or without systemic symptoms / signs)	<ul style="list-style-type: none"> <li>• Respiratory syncytial virus</li> </ul>	<ul style="list-style-type: none"> <li>• Rhinovirus</li> <li>• Adenovirus</li> <li>• Human metapneumovirus</li> <li>• Parainfluenza Type 3</li> </ul>	<ul style="list-style-type: none"> <li>• Influenza Type A</li> <li>• Influenza Type B</li> <li>• Coronavirus</li> <li>• Enterovirus</li> </ul>	(47, 48)

	1. Acute pneumonia	<ul style="list-style-type: none"> <li>• Influenza Type A</li> </ul>	<ul style="list-style-type: none"> <li>• Influenza Type B</li> <li>• Respiratory syncytial virus</li> <li>• Rhinovirus</li> <li>• Adenovirus</li> </ul>	<ul style="list-style-type: none"> <li>• Parainfluenza Type 3</li> <li>• Human metapneumovirus</li> <li>• Measles virus</li> <li>• Enterovirus</li> <li>• Coronavirus</li> <li>• Varicella virus</li> <li>• Epstein Barr virus</li> <li>• Cytomegalovirus</li> </ul>	(47, 48)
--	--------------------	--	---	--	----------

**Alternate “historical” terminology for clinical syndromes:**

\*: Acute viral rhinosinusitis / rhinopharyngitis (common): Also referred to as “Coryza” / “Common cold” / “Viral upper respiratory tract infection (URTI)”

\*\* : Acute viral rhinosinusitis / rhinopharyngitis with systemic symptoms / signs: also referred to as “flu” or “flu-like” syndrome” / “Influenza-like” syndrome: NB The clinical syndrome can be associated with several pathogens not only influenza viruses. The World Health Organisation (WHO) influenza-like-illness case definition is as follows: “An acute respiratory infection with: measured fever of  $\geq 38\text{ C}^\circ$ , and cough; with onset within the last 10 days”. [REF: <https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/case-definitions-for-ili-and-sari>]

\*\*\*: Acute viral laryngotracheobronchitis: also referred to “croup”

**Supplementary Table S4: Special investigations to diagnose possible complications in other organs / organ systems that are associated with selected pathogens causing acute respiratory infections (ARInf)**

Specific organ / organ system	Complications	Special investigations to diagnose complication/s
<b>Respiratory tract (regional complications)</b>	Pneumonia	<ul style="list-style-type: none"> <li>• Chest X-Ray</li> <li>• Lung Computerised Tomogram (CT) scan</li> </ul>
<b>Cardiovascular</b>	Myocarditis / pericarditis	<ul style="list-style-type: none"> <li>• Triad of tests (resting electrocardiogram (ECG), Echocardiogram, Serum troponins *)</li> <li>• Additional tests to consider: <ul style="list-style-type: none"> <li>○ 72hr Holter Electrocardiogram</li> <li>○ Cardiac Magnetic Resonance (CMR) Imaging</li> <li>○ Stress electrocardiography (post-acute infection before returning to sport)</li> </ul> </li> </ul>
	Thrombo-embolic disease	<ul style="list-style-type: none"> <li>• D-dimer</li> <li>• Vascular ultrasound</li> </ul>
<b>Nervous system</b>	Meningitis	<ul style="list-style-type: none"> <li>• Lumbar puncture</li> </ul>
	Autonomic dysfunction (e.g. POTS, IST)	<ul style="list-style-type: none"> <li>• Heart rate response to active standing or head-up tilt with blood pressure measurement</li> <li>• Heart rate variability (HRV)</li> </ul>
	Cognitive dysfunction	<ul style="list-style-type: none"> <li>• Neurocognitive testing (in conjunction with neurologist / neuropsychologist)</li> </ul>
<b>Renal / bladder</b>	Nephritis / Acute kidney injury	<ul style="list-style-type: none"> <li>• Serum urea and electrolytes</li> <li>• Glomerular filtration rate (GFR) - estimated and measured</li> </ul>
<b>Gastrointestinal</b>	Hepatitis	<ul style="list-style-type: none"> <li>• Liver function tests</li> </ul>
<b>Musculoskeletal</b>	Myositis	<ul style="list-style-type: none"> <li>• Resting serum creatine kinase (CK) activity</li> </ul>
	Rhabdomyolysis	<ul style="list-style-type: none"> <li>• Positive urine dipstick interpreted with urine microscopy</li> <li>• Resting and 48hr post exercise serum creatine kinase (CK) activity</li> <li>• Serum myoglobin concentration</li> </ul>

POTS: Postural orthostatic tachycardia syndrome; IST: Inappropriate Sinus Tachycardia

\*: May be raised in athletes post-exercise



**References:**

1. Royston L, Tapparel C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. *Viruses*. 2016;8(1).
2. Branche AR, Falsey AR, editors. Parainfluenza virus infection. *Sem Respir Crit Care Med*; 2016: Thieme Medical Publishers.
3. Mosnier A, Caini S, Daviaud I, et al. Clinical characteristics are similar across Type A and B Influenza virus infections. *PLOS ONE*. 2015;10(9):e0136186.
4. Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus--a comprehensive review. *Clin Rev Allergy Immunol*. 2013;45(3):331-79.
5. To KKW, Yip CCY, Yuen K-Y. Rhinovirus – From bench to bedside. *Journal of the Formosan Medical Association*. 2017;116(7):496-504.
6. Royston L, Tapparel C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. *Viruses*. 2016;8(1):16.
7. Wolford RW, Goyal A, Belgam Syed SY, et al. Pharyngitis: StatPearls Publishing, Treasure Island (FL); 2021 2021.
8. Pawełczyk M, Kowalski ML. The role of human parainfluenza virus infections in the immunopathology of the respiratory tract. *Curr Allergy Asthma Rep*. 2017;17(3):16.
9. Brink AJ, Cotton MF, Feldman C, et al. Updated recommendations for the management of upper respiratory tract infections in South Africa 2015.
10. B'Krong NTT, Minh NNQ, Qui PT, et al. Enterovirus serotypes in patients with central nervous system and respiratory infections in Viet Nam 1997–2010. *Virology J*. 2018;15(1):69.
11. Ngeow Y-F, Suwanjutha S, Chantarojanasriri T, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2005;9(3):144-53.
12. Panda S, Mohakud NK, Pena L, et al. Human metapneumovirus: review of an important respiratory pathogen. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2014;25:45-52.
13. Sharma L, Losier A, Tolbert T, et al. Atypical pneumonia: updates on legionella, chlamydia, and mycoplasma pneumonia. *Clinics in Chest Medicine*. 2017;38(1):45-58.
14. Hall CB, Simões EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. *Curr Top Microbiol Immunol*. 2013;372:39-57.
15. O'Gorman C, McHenry E, Coyle PV. Human metapneumovirus in adults: a short case series. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2006;25(3):190-2.
16. Vandini S, Biagi C, Lanari M. Respiratory Syncytial Virus: the influence of serotype and genotype variability on clinical course of infection. *International Journal of Molecular Sciences*. 2017;18(8):1717.

17. Weinberger R, Riffelmann M, Kennerknecht N, et al. Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. 2018;37(4):665-72.
18. Martinez MW, Tucker AM, Bloom OJ, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening. *JAMA Cardiology*. 2021;6(7):745-52.
19. Starekova J, Bluemke DA, Bradham WS, et al. Evaluation for myocarditis in competitive student athletes recovering from Coronavirus Disease 2019 With cardiac magnetic resonance imaging. *JAMA Cardiol*. 2021;6(8):945-50.
20. Szabó L, Juhász V, Dohy Z, et al. Is cardiac involvement prevalent in highly trained athletes after SARS-CoV-2 infection? A cardiac magnetic resonance study using sex-matched and age-matched controls. *British Journal of Sports Medicine*. 2021:bjsports-2021-104576.
21. Bahri O, Rezig D, Nejma-Oueslati BB, et al. Enteroviruses in Tunisia: virological surveillance over 12 years (1992–2003). *J Med Microbiol*. 2005;54(1):63-9.
22. Harvala H, Broberg E, Benschop K, et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. *J Clin Virol*. 2018;101:11-7.
23. Brito D, Meester S, Yanamala N, et al. High prevalence of pericardial involvement in college student athletes recovering from COVID-19. *JACC Cardiovasc Imaging*. 2021;14(3):541-55.
24. Petek BJ, Moulson N, Baggish AL, et al. Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA). *British Journal of Sports Medicine*. 2021:bjsports-2021-104644.
25. van Hattum JC, Spies JL, Verwijs SM, et al. Cardiac abnormalities in athletes after SARS-CoV-2 infection: a systematic review. *BMJ open sport & exercise medicine*. 2021;7(4):e001164-e.
26. Lynch JP, Fishbein M, Echavarría M, editors. Adenovirus. *Sem Respir Crit Care Med*; 2011: © Thieme Medical Publishers.
27. Desai AD, Boursiquot BC, Moore CJ, et al. Autonomic dysfunction post-acute COVID-19 infection. *HeartRhythm Case Rep*. 2021.
28. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. *Immunol Res*. 2021;69(2):205-11.
29. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. *Clinical medicine (London, England)*. 2021;21(1):e63-e7.
30. Taquet M, Luciano S, R Geddes J, et al. Bidirectional associations between COVID-19 and psychiatric disorder: a study of 62,354 COVID-19 cases. *medRxiv*. 2020:2020.08.14.20175190.
31. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. *EClinicalMedicine*. 2020;25:100484.
32. Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID-19. *EClinicalMedicine*. 2021;39:101044.

33. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *eClinicalMedicine*. 2021;38.
34. Buchwald DS, Rea TD, Katon WJ, et al. Acute infectious mononucleosis: characteristics of patients who report failure to recover. *Am J Med*. 2000;109(7):531-7.
35. Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics*. 2009;124(1):189-93.
36. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLOS ONE*. 2020;15(11):e0240784.
37. Gross O, Moerer O, Weber M, et al. COVID-19-associated nephritis: early warning for disease severity and complications? *Lancet (London, England)*. 2020;395(10236):e87-e8.
38. Bouvier M, Chen W-J, Arnold JC, et al. Species-specific clinical characteristics of human coronavirus infection among otherwise healthy adolescents and adults. *Influenza and other respiratory viruses*. 2018;12(2):299-303.
39. Chan PA, Mermel LA, Andrea SB, et al. Distinguishing characteristics between pandemic 2009–2010 Influenza A (H1N1) and other viruses in patients hospitalized with respiratory illness. *PLOS ONE*. 2011;6(9):e24734.
40. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. *J Gastroenterol Hepatol*. 2020;35(5):744-8.
41. Kunutsor SK, Laukkanen JA. Hepatic manifestations and complications of COVID-19: A systematic review and meta-analysis. *J Infect*. 2020;81(3):e72-e4.
42. Uslu S. Myositis due to COVID-19. *Postgrad Med J*. 2021;97(1148):399.
43. Beydon M, Chevalier K, Al Tabaa O, et al. Myositis as a manifestation of SARS-CoV-2. *Annals of the Rheumatic Diseases*. 2021;80(3):e42-e.
44. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. *The Lancet Rheumatology*. 2020;2(11):e655-e7.
45. Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain, behavior, and immunity*. 2020;89:594-600.
46. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. 2020;7(7):611-27.
47. Treanor J. Respiratory infections. 4 ed. D R, R W, F H, editors. Washington DC: ASM Press; 2017.
48. Mäkelä MJ, Puhakka T, Ruuskanen O, et al. Viruses and bacteria in the etiology of the common cold. *Journal of clinical microbiology*. 1998;36(2):539-42.
49. Bellei N, Carraro E, Perosa A, et al. Acute respiratory infection and influenza-like illness viral etiologies in Brazilian adults. *Journal of medical virology*. 2008;80(10):1824-7.
50. Howard PF, McCaw JM, Richmond PC, et al. Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial. *Influenza and other respiratory viruses*. 2013;7(3):330-9.

51. Kelly H, Birch C. The causes and diagnosis of influenza-like illness. *Australian family physician*. 2004;33(5):305-9.
52. Renois F, Talmud D, Huguenin A, et al. Rapid detection of respiratory tract viral infections and coinfections in patients with influenza-like illnesses by use of reverse transcription-PCR DNA microarray systems. *Journal of clinical microbiology*. 2010;48(11):3836-42.
53. Santamaría C, Urueña A, Videla C, et al. Epidemiological study of influenza virus infections in young adult outpatients from Buenos Aires, Argentina. *Influenza and other respiratory viruses*. 2008;2(4):131-4.
54. Schnepf N, Resche-Rigon M, Chaillon A, et al. High burden of non-influenza viruses in influenza-like illness in the early weeks of H1N1v epidemic in France. *PLOS ONE*. 2011;6(8):e23514.